BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rebouissou S, Amessou M, Couchy G, Poussin K, Imbeaud S, Pilati C, Izard T, Balabaud C, Bioulac-Sage P, Zucman-Rossi J. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature. 2009;457:200-204. [PMID: 19020503 DOI: 10.1038/nature07475] [Cited by in Crossref: 354] [Cited by in F6Publishing: 316] [Article Influence: 25.3] [Reference Citation Analysis]
Number Citing Articles
1 O’Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med. 2013;368:161-170. [PMID: 23301733 DOI: 10.1056/nejmra1202117] [Cited by in Crossref: 476] [Cited by in F6Publishing: 247] [Article Influence: 52.9] [Reference Citation Analysis]
2 Fukui H, Watari J, Zhang X, Ran Y, Tomita T, Oshima T, Hirota S, Miwa H. Phosphorylated STAT3 expression linked to SOCS3 methylation is associated with proliferative ability of gastric mucosa in patients with early gastric cancer. Oncol Lett 2020;19:3542-50. [PMID: 32269628 DOI: 10.3892/ol.2020.11462] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Sosonkina N, Starenki D, Park JI. The Role of STAT3 in Thyroid Cancer. Cancers (Basel) 2014;6:526-44. [PMID: 24662939 DOI: 10.3390/cancers6010526] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
4 Buchert M, Athineos D, Abud HE, Burke ZD, Faux MC, Samuel MS, Jarnicki AG, Winbanks CE, Newton IP, Meniel VS, Suzuki H, Stacker SA, Näthke IS, Tosh D, Huelsken J, Clarke AR, Heath JK, Sansom OJ, Ernst M. Genetic dissection of differential signaling threshold requirements for the Wnt/beta-catenin pathway in vivo. PLoS Genet 2010;6:e1000816. [PMID: 20084116 DOI: 10.1371/journal.pgen.1000816] [Cited by in Crossref: 67] [Cited by in F6Publishing: 61] [Article Influence: 5.6] [Reference Citation Analysis]
5 Sakellariou S, Al-Hussaini H, Scalori A, Samyn M, Heaton N, Portmann B, Tobal K, Quaglia A. Hepatocellular adenoma in glycogen storage disorder type I: a clinicopathological and molecular study. Histopathology. 2012;60:E58-E65. [PMID: 22372484 DOI: 10.1111/j.1365-2559.2011.04153.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
6 Confeld MI, Mamnoon B, Feng L, Jensen-Smith H, Ray P, Froberg J, Kim J, Hollingsworth MA, Quadir M, Choi Y, Mallik S. Targeting the Tumor Core: Hypoxia-Responsive Nanoparticles for the Delivery of Chemotherapy to Pancreatic Tumors. Mol Pharm 2020;17:2849-63. [PMID: 32521162 DOI: 10.1021/acs.molpharmaceut.0c00247] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
7 Wu WY, Li J, Wu ZS, Zhang CL, Meng XL. STAT3 activation in monocytes accelerates liver cancer progression. BMC Cancer 2011;11:506. [PMID: 22136659 DOI: 10.1186/1471-2407-11-506] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 4.2] [Reference Citation Analysis]
8 Mauer J, Denson JL, Brüning JC. Versatile functions for IL-6 in metabolism and cancer. Trends Immunol 2015;36:92-101. [PMID: 25616716 DOI: 10.1016/j.it.2014.12.008] [Cited by in Crossref: 196] [Cited by in F6Publishing: 175] [Article Influence: 28.0] [Reference Citation Analysis]
9 Albrengues J, Bertero T, Grasset E, Bonan S, Maiel M, Bourget I, Philippe C, Herraiz Serrano C, Benamar S, Croce O, Sanz-Moreno V, Meneguzzi G, Feral CC, Cristofari G, Gaggioli C. Epigenetic switch drives the conversion of fibroblasts into proinvasive cancer-associated fibroblasts. Nat Commun 2015;6:10204. [PMID: 26667266 DOI: 10.1038/ncomms10204] [Cited by in Crossref: 154] [Cited by in F6Publishing: 150] [Article Influence: 22.0] [Reference Citation Analysis]
10 Sun L, Sui L, Cong X, Ma K, Ma X, Huang Y, Fan C, Fu X, Ma K. Low incidence of IL6ST (gp130) mutations in exon 6 in lung cancer of a Chinese cohort. Cancer Genet. 2014;207:291-298. [PMID: 25242236 DOI: 10.1016/j.cancergen.2014.07.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
11 Hatting M, Spannbauer M, Peng J, Al Masaoudi M, Sellge G, Nevzorova YA, Gassler N, Liedtke C, Cubero FJ, Trautwein C. Lack of gp130 expression in hepatocytes attenuates tumor progression in the DEN model. Cell Death Dis 2015;6:e1667. [PMID: 25741592 DOI: 10.1038/cddis.2014.590] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
12 Bellamy COC, Maxwell RS, Prost S, Azodo IA, Powell JJ, Manning JR. The value of immunophenotyping hepatocellular adenomas: consecutive resections at one UK centre: Hepatocellular adenomas. Histopathology 2013;62:431-45. [DOI: 10.1111/his.12011] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
13 Ernst M, Putoczki TL. Stat3: Linking inflammation to (gastrointestinal) tumourigenesis. Clin Exp Pharmacol Physiol 2012;39:711-8. [DOI: 10.1111/j.1440-1681.2011.05659.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
14 Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, Osterreicher CH, Takahashi H, Karin M. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell. 2010;140:197-208. [PMID: 20141834 DOI: 10.1016/j.cell.2009.12.052] [Cited by in Crossref: 1068] [Cited by in F6Publishing: 1023] [Article Influence: 89.0] [Reference Citation Analysis]
15 Hatziapostolou M, Polytarchou C, Aggelidou E, Drakaki A, Poultsides GA, Jaeger SA, Ogata H, Karin M, Struhl K, Hadzopoulou-Cladaras M. An HNF4α-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis. Cell. 2011;147:1233-1247. [PMID: 22153071 DOI: 10.1016/j.cell.2011.10.043] [Cited by in Crossref: 331] [Cited by in F6Publishing: 331] [Article Influence: 33.1] [Reference Citation Analysis]
16 Kumagawa M, Matsumoto N, Watanabe Y, Hirayama M, Miura T, Nakagawara H, Ogawa M, Matsuoka S, Moriyama M, Takayama T, Sugitani M. Contrast-enhanced ultrasonographic findings of serum amyloid A-positive hepatocellular neoplasm: Does hepatocellular adenoma arise in cirrhotic liver? World J Hepatol 2016; 8(26): 1110-1115 [PMID: 27660679 DOI: 10.4254/wjh.v8.i26.1110] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
17 Jin L, Liu WR, Tian MX, Fan J, Shi YH. The SphKs/S1P/S1PR1 axis in immunity and cancer: more ore to be mined. World J Surg Oncol 2016;14:131. [PMID: 27129720 DOI: 10.1186/s12957-016-0884-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
18 Wang K, Vella AT. Regulatory T Cells and Cancer: A Two-Sided Story. Immunol Invest 2016;45:797-812. [PMID: 27603750 DOI: 10.1080/08820139.2016.1197242] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.7] [Reference Citation Analysis]
19 Subramaniam A, Shanmugam MK, Perumal E, Li F, Nachiyappan A, Dai X, Swamy SN, Ahn KS, Kumar AP, Tan BK, Hui KM, Sethi G. Potential role of signal transducer and activator of transcription (STAT)3 signaling pathway in inflammation, survival, proliferation and invasion of hepatocellular carcinoma. Biochim Biophys Acta 2013;1835:46-60. [PMID: 23103770 DOI: 10.1016/j.bbcan.2012.10.002] [Cited by in Crossref: 57] [Cited by in F6Publishing: 123] [Article Influence: 5.7] [Reference Citation Analysis]
20 Dokmak S, Cauchy F, Belghiti J. Resection, transplantation and local regional therapies for liver adenomas. Expert Rev Gastroenterol Hepatol 2014;8:803-10. [PMID: 24957321 DOI: 10.1586/17474124.2014.917957] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
21 Tu T, Budzinska MA, Maczurek AE, Cheng R, Di Bartolomeo A, Warner FJ, McCaughan GW, McLennan SV, Shackel NA. Novel aspects of the liver microenvironment in hepatocellular carcinoma pathogenesis and development. Int J Mol Sci. 2014;15:9422-9458. [PMID: 24871369 DOI: 10.3390/ijms15069422] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 5.9] [Reference Citation Analysis]
22 Wang X, Zhang X. Hepatocellular adenoma: Where are we now? World J Gastroenterol 2022; 28(14): 1384-1393 [DOI: 10.3748/wjg.v28.i14.1384] [Reference Citation Analysis]
23 Balaha M, Kandeel S, Barakat W. Carvedilol suppresses circulating and hepatic IL-6 responsible for hepatocarcinogenesis of chronically damaged liver in rats. Toxicology and Applied Pharmacology 2016;311:1-11. [DOI: 10.1016/j.taap.2016.10.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
24 Liau SS, Qureshi MS, Praseedom R, Huguet E. Molecular pathogenesis of hepatic adenomas and its implications for surgical management. J Gastrointest Surg. 2013;17:1869-1882. [PMID: 23835731 DOI: 10.1007/s11605-013-2274-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
25 Rose-John S. Blocking only the bad side of IL-6 in inflammation and cancer. Cytokine 2021;148:155690. [PMID: 34474215 DOI: 10.1016/j.cyto.2021.155690] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Lamertz L, Floss DM, Scheller J. Combined deletion of the fibronectin-type III domains and the stalk region results in ligand-independent, constitutive activation of the Interleukin 6 signal-transducing receptor gp130. Cytokine 2018;110:428-34. [DOI: 10.1016/j.cyto.2018.05.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
27 Fathi N, Rashidi G, Khodadadi A, Shahi S, Sharifi S. STAT3 and apoptosis challenges in cancer. Int J Biol Macromol 2018;117:993-1001. [PMID: 29782972 DOI: 10.1016/j.ijbiomac.2018.05.121] [Cited by in Crossref: 65] [Cited by in F6Publishing: 70] [Article Influence: 16.3] [Reference Citation Analysis]
28 Fonseca S, Hoton D, Dardenne S, Annet L, Hubert C, Godecharles S, Jouret-Mourin A, Reding R, Otte JB, Rahier J, Gigot JF, Sempoux C. Histological and immunohistochemical revision of hepatocellular adenomas: a learning experience. Int J Hepatol 2013;2013:398308. [PMID: 23533787 DOI: 10.1155/2013/398308] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
29 Liu H, Ye Z, Kim Y, Sharkis S, Jang YY. Generation of endoderm-derived human induced pluripotent stem cells from primary hepatocytes. Hepatology. 2010;51:1810-1819. [PMID: 20432258 DOI: 10.1002/hep.23626] [Cited by in Crossref: 178] [Cited by in F6Publishing: 160] [Article Influence: 14.8] [Reference Citation Analysis]
30 Jeric I, Maurer G, Cavallo AL, Raguz J, Desideri E, Tarkowski B, Parrini M, Fischer I, Zatloukal K, Baccarini M. A cell-autonomous tumour suppressor role of RAF1 in hepatocarcinogenesis. Nat Commun 2016;7:13781. [PMID: 28000790 DOI: 10.1038/ncomms13781] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
31 Borgia M, Dal Bo M, Toffoli G. Role of Virus-Related Chronic Inflammation and Mechanisms of Cancer Immune-Suppression in Pathogenesis and Progression of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:4387. [PMID: 34503196 DOI: 10.3390/cancers13174387] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
32 Sommer J, Effenberger T, Volpi E, Waetzig GH, Bernhardt M, Suthaus J, Garbers C, Rose-john S, Floss DM, Scheller J. Constitutively Active Mutant gp130 Receptor Protein from Inflammatory Hepatocellular Adenoma Is Inhibited by an Anti-gp130 Antibody That Specifically Neutralizes Interleukin 11 Signaling. Journal of Biological Chemistry 2012;287:13743-51. [DOI: 10.1074/jbc.m112.349167] [Cited by in Crossref: 26] [Article Influence: 2.6] [Reference Citation Analysis]
33 Tye H, Kennedy CL, Najdovska M, McLeod L, McCormack W, Hughes N, Dev A, Sievert W, Ooi CH, Ishikawa TO. STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation. Cancer Cell. 2012;22:466-478. [PMID: 23079657 DOI: 10.1016/j.ccr.2012.08.010] [Cited by in Crossref: 169] [Cited by in F6Publishing: 149] [Article Influence: 18.8] [Reference Citation Analysis]
34 Kahn ME, French S, Wang HL. Hepatocellular Adenoma: Morphological and Molecular Variants and Distinction From Well-Differentiated Hepatocellular Carcinoma. Pathology Case Reviews 2009;14:13-20. [DOI: 10.1097/pcr.0b013e31819c4956] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
35 Zhang H, Means S, Schultz AR, Watanabe-Smith K, Medeiros BC, Bottomly D, Wilmot B, McWeeney SK, Kükenshöner T, Hantschel O, Tyner JW. Unpaired Extracellular Cysteine Mutations of CSF3R Mediate Gain or Loss of Function. Cancer Res 2017;77:4258-67. [PMID: 28652245 DOI: 10.1158/0008-5472.CAN-17-1052] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
36 Di Pietropaolo M, Briani C, Pilozzi E, Carbonetti F, David V, Iannicelli E. Gd-EOB-DTPA-Enhanced Magnetic Resonance Findings of a Giant Inflammatory Hepatocellular Adenoma: a Case Report and Review of the Literature. J Gastrointest Cancer 2015;46:421-5. [PMID: 25894634 DOI: 10.1007/s12029-015-9715-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
37 Evason KJ, Grenert JP, Ferrell LD, Kakar S. Atypical hepatocellular adenoma-like neoplasms with β-catenin activation show cytogenetic alterations similar to well-differentiated hepatocellular carcinomas. Hum Pathol. 2013;44:750-758. [PMID: 23084586 DOI: 10.1016/j.humpath.2012.07.019] [Cited by in Crossref: 58] [Cited by in F6Publishing: 41] [Article Influence: 5.8] [Reference Citation Analysis]
38 Park DW, Lee HK, Jeong TW, Kim JS, Bae YS, Chin BR, Baek SH. The JAK2-Akt-glycogen synthase kinase-3β signaling pathway is involved in toll-like receptor 2-induced monocyte chemoattractant protein-1 regulation. Mol Med Rep 2012;5:1063-7. [PMID: 22218715 DOI: 10.3892/mmr.2012.741] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
39 Klompenhouwer AJ, de Man RA, Dioguardi Burgio M, Vilgrain V, Zucman-Rossi J, Ijzermans JNM. New insights in the management of Hepatocellular Adenoma. Liver Int 2020;40:1529-37. [PMID: 32464711 DOI: 10.1111/liv.14547] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
40 Guyader D, Latournerie M. [Incidental ultrasound finding of a 3 cm liver nodule in a 45-year-old woman taking hormonal substitution after hysterectomy performed for cervix carcinoma]. Gastroenterol Clin Biol 2009;33:F60-7. [PMID: 19766417 DOI: 10.1016/j.gcb.2009.08.006] [Reference Citation Analysis]
41 Materna-Kiryluk A, Pollak A, Gawalski K, Szczawinska-Poplonyk A, Rydzynska Z, Sosnowska A, Cukrowska B, Gasperowicz P, Konopka E, Pietrucha B, Grzywa TM, Banaszak-Ziemska M, Niedziela M, Skalska-Sadowska J, Stawiński P, Śladowski D, Nowis D, Ploski R. Mosaic IL6ST variant inducing constitutive GP130 cytokine receptor signaling as a cause of neonatal onset immunodeficiency with autoinflammation and dysmorphy. Hum Mol Genet 2021;30:226-33. [PMID: 33517393 DOI: 10.1093/hmg/ddab035] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
42 Schmidt-arras D, Müller M, Stevanovic M, Horn S, Schütt A, Bergmann J, Wilkens R, Lickert A, Rose-john S. Oncogenic deletion mutants of gp130 signal from intracellular compartments. Journal of Cell Science. [DOI: 10.1242/jcs.130294] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
43 Feng T, Cao W, Shen W, Zhang L, Gu X, Guo Y, Tsai HI, Liu X, Li J, Zhang J, Li S, Wu F, Liu Y. Arctigenin inhibits STAT3 and exhibits anticancer potential in human triple-negative breast cancer therapy. Oncotarget 2017;8:329-44. [PMID: 27861147 DOI: 10.18632/oncotarget.13393] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 10.0] [Reference Citation Analysis]
44 Bonito NA, Drechsler J, Stoecker S, Carmo CR, Seckl MJ, Hermanns HM, Costa-pereira AP. Control of gp130 expression by the mitogen-activated protein kinase ERK2. Oncogene 2014;33:2255-63. [DOI: 10.1038/onc.2013.159] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
45 Murakami M, Okuyama Y, Ogura H, Asano S, Arima Y, Tsuruoka M, Harada M, Kanamoto M, Sawa Y, Iwakura Y, Takatsu K, Kamimura D, Hirano T. Local microbleeding facilitates IL-6- and IL-17-dependent arthritis in the absence of tissue antigen recognition by activated T cells. J Exp Med 2011;208:103-14. [PMID: 21220456 DOI: 10.1084/jem.20100900] [Cited by in F6Publishing: 70] [Reference Citation Analysis]
46 Katabathina VS, Menias CO, Shanbhogue AK, Jagirdar J, Paspulati RM, Prasad SR. Genetics and imaging of hepatocellular adenomas: 2011 update. Radiographics. 2011;31:1529-1543. [PMID: 21997980 DOI: 10.1148/rg.316115527] [Cited by in Crossref: 106] [Cited by in F6Publishing: 77] [Article Influence: 10.6] [Reference Citation Analysis]
47 Kamali K, Schmelzle M, Kamali C, Brunnbauer P, Splith K, Leder A, Berndt N, Hillebrandt KH, Raschzok N, Feldbrügge L, Felsenstein M, Gaßner J, Ritschl P, Lurje G, Schöning W, Benzing C, Pratschke J, Krenzien F. Sensing Acute Cellular Rejection in Liver Transplant Patients Using Liver-Derived Extracellular Particles: A Prospective, Observational Study. Front Immunol 2021;12:647900. [PMID: 34025656 DOI: 10.3389/fimmu.2021.647900] [Reference Citation Analysis]
48 Blanc JF, Frulio N, Chiche L, Bioulac-Sage P, Balabaud C. Hepatocellular adenoma management: advances but still a long way to go. Hepat Oncol. 2015;2:171-180. [PMID: 30190996 DOI: 10.2217/hep.14.41] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
49 Khatibi S, Babon J, Wagner J, Manton JH, Tan CW, Zhu H, Wormald S, Burgess AW. TGF-β and IL-6 family signalling crosstalk: an integrated model. Growth Factors 2017;35:100-24. [DOI: 10.1080/08977194.2017.1363746] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
50 Sun H, Kim E, Ryu J, Lee H, Shin EA, Lee M, Lee H, Lee JH, Yoon JH, Song DG, Kim S, Lee JW. TM4SF5-mediated liver malignancy involves NK cell exhaustion-like phenotypes. Cell Mol Life Sci 2021. [PMID: 34921636 DOI: 10.1007/s00018-021-04051-x] [Reference Citation Analysis]
51 Bedossa P, Paradis V, Zucman-rossi J. Cellular and Molecular Techniques. Macsween's Pathology of the Liver. Elsevier; 2018. pp. 88-110. [DOI: 10.1016/b978-0-7020-6697-9.00002-9] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
52 Ling HY, Yang Z, Wang PJ, Sun Y, Ju SG, Li J, Fu JX. Diffuse large B-cell lymphoma-derived exosomes push macrophage polarization toward M2 phenotype via GP130/STAT3 signaling pathway. Chem Biol Interact 2021;352:109779. [PMID: 34922904 DOI: 10.1016/j.cbi.2021.109779] [Reference Citation Analysis]
53 Ho Y, Tsao S, Zeng M, Lui VWY. STAT3 as a therapeutic target for Epstein-Barr virus (EBV) – associated nasopharyngeal carcinoma. Cancer Letters 2013;330:141-9. [DOI: 10.1016/j.canlet.2012.11.052] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
54 Wang Y, Ma H, Zhao C, Liu T, Yan D, Jou D, Li H, Zhang C, Lü J, Li C, Lin J, Li S, Lin L. Growth-suppressive activity of raloxifene on liver cancer cells by targeting IL-6/GP130 signaling. Oncotarget 2017;8:33683-93. [PMID: 28430601 DOI: 10.18632/oncotarget.16898] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
55 Lee H, Deng J, Kujawski M, Yang C, Liu Y, Herrmann A, Kortylewski M, Horne D, Somlo G, Forman S. STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors. Nat Med. 2010;16:1421-1428. [PMID: 21102457 DOI: 10.1038/nm.2250] [Cited by in Crossref: 261] [Cited by in F6Publishing: 265] [Article Influence: 21.8] [Reference Citation Analysis]
56 Smoot RL, Nagorney DM, Chandan VS, Que FG, Schleck CD, Harmsen WS, Kendrick ML. Resection of hepatocellular carcinoma in patients without cirrhosis. Br J Surg. 2011;98:697-703. [PMID: 21280030 DOI: 10.1002/bjs.7401] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 2.7] [Reference Citation Analysis]
57 Giraldez MD, Carneros D, Garbers C, Rose-John S, Bustos M. New insights into IL-6 family cytokines in metabolism, hepatology and gastroenterology. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34211157 DOI: 10.1038/s41575-021-00473-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
58 European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines on the management of benign liver tumours. J Hepatol. 2016;65:386-398. [PMID: 27085809 DOI: 10.1016/j.jhep.2016.04.001] [Cited by in Crossref: 201] [Cited by in F6Publishing: 153] [Article Influence: 33.5] [Reference Citation Analysis]
59 Lokau J, Garbers C. Activating mutations of the gp130/JAK/STAT pathway in human diseases. Adv Protein Chem Struct Biol 2019;116:283-309. [PMID: 31036294 DOI: 10.1016/bs.apcsb.2018.11.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
60 Silver JS, Hunter CA. gp130 at the nexus of inflammation, autoimmunity, and cancer. J Leukoc Biol. 2010;88:1145-1156. [PMID: 20610800 DOI: 10.1189/jlb.0410217] [Cited by in Crossref: 159] [Cited by in F6Publishing: 155] [Article Influence: 13.3] [Reference Citation Analysis]
61 Ma H, Yan D, Wang Y, Shi W, Liu T, Zhao C, Huo S, Duan J, Tao J, Zhai M, Luo P, Guo J, Tian L, Mageta L, Jou D, Zhang C, Li C, Lin J, Lv J, Li S, Lin L. Bazedoxifene exhibits growth suppressive activity by targeting interleukin-6/glycoprotein 130/signal transducer and activator of transcription 3 signaling in hepatocellular carcinoma. Cancer Sci. 2019;110:950-961. [PMID: 30648776 DOI: 10.1111/cas.13940] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
62 Bollrath J, Greten FR. IKK/NF-kappaB and STAT3 pathways: central signalling hubs in inflammation-mediated tumour promotion and metastasis. EMBO Rep. 2009;10:1314-1319. [PMID: 19893576 DOI: 10.1038/embor.2009.243] [Cited by in Crossref: 277] [Cited by in F6Publishing: 256] [Article Influence: 21.3] [Reference Citation Analysis]
63 Bourdeaut F, Janoueix-lerosey I, Lucchesi C, Paris R, Ribeiro A, de Pontual L, Amiel J, Lyonnet S, Pierron G, Michon J, Peuchmaur M, Delattre O. Cholinergic switch associated with morphological differentiation in neuroblastoma: Cholinergic switch in neuroblastoma. J Pathol 2009;219:463-72. [DOI: 10.1002/path.2614] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
64 Xu S, Neamati N. gp130: a promising drug target for cancer therapy. Expert Opinion on Therapeutic Targets 2013;17:1303-28. [DOI: 10.1517/14728222.2013.830105] [Cited by in Crossref: 39] [Cited by in F6Publishing: 61] [Article Influence: 4.3] [Reference Citation Analysis]
65 Shkhyan R, Lee S, Gullo F, Li L, Peleli M, Carlstrom M, Chagin AS, Banks NW, Limfat S, Liu NQ, Evseenko D. Genetic ablation of adenosine receptor A3 results in articular cartilage degeneration. J Mol Med (Berl) 2018;96:1049-60. [PMID: 30088034 DOI: 10.1007/s00109-018-1680-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
66 Floss DM, Scheller J. Naturally occurring and synthetic constitutive-active cytokine receptors in disease and therapy. Cytokine Growth Factor Rev 2019;47:1-20. [PMID: 31147158 DOI: 10.1016/j.cytogfr.2019.05.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
67 Ye Y, An Y, Wang M, Liu H, Guan L, Wang Z, Li W. Expression of Carboxypeptidase X M14 Family Member 2 Accelerates the Progression of Hepatocellular Carcinoma via Regulation of the gp130/JAK2/Stat1 Pathway. Cancer Manag Res 2020;12:2353-64. [PMID: 32280274 DOI: 10.2147/CMAR.S228984] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Taniguchi K, Wu LW, Grivennikov SI, de Jong PR, Lian I, Yu FX, Wang K, Ho SB, Boland BS, Chang JT, Sandborn WJ, Hardiman G, Raz E, Maehara Y, Yoshimura A, Zucman-Rossi J, Guan KL, Karin M. A gp130-Src-YAP module links inflammation to epithelial regeneration. Nature 2015;519:57-62. [PMID: 25731159 DOI: 10.1038/nature14228] [Cited by in Crossref: 394] [Cited by in F6Publishing: 359] [Article Influence: 56.3] [Reference Citation Analysis]
69 Okada Y, Watanabe T, Shoji T, Taguchi K, Ogo N, Asai A. Visualization and quantification of dynamic STAT3 homodimerization in living cells using homoFluoppi. Sci Rep 2018;8:2385. [PMID: 29402895 DOI: 10.1038/s41598-018-20234-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
70 Goltz D, Fischer HP. [Hepatocellular tumours in noncirrhotic liver tissue]. Pathologe 2015;36:597-606; quiz 607-8. [PMID: 26496997 DOI: 10.1007/s00292-015-0113-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
71 Zhang C, Cherifi I, Nygaard M, Haxholm GW, Bogorad RL, Bernadet M, England P, Broutin I, Kragelund BB, Guidotti JE, Goffin V. Residue 146 regulates prolactin receptor folding, basal activity and ligand-responsiveness: potential implications in breast tumorigenesis. Mol Cell Endocrinol 2015;401:173-88. [PMID: 25524456 DOI: 10.1016/j.mce.2014.12.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
72 Coulouarn C, Corlu A, Glaise D, Guénon I, Thorgeirsson SS, Clément B. Hepatocyte-stellate cell cross-talk in the liver engenders a permissive inflammatory microenvironment that drives progression in hepatocellular carcinoma. Cancer Res. 2012;72:2533-2542. [PMID: 22419664 DOI: 10.1158/0008-5472.can-11-3317] [Cited by in Crossref: 133] [Cited by in F6Publishing: 67] [Article Influence: 13.3] [Reference Citation Analysis]
73 Schupp J, Krebs FK, Zimmer N, Trzeciak E, Schuppan D, Tuettenberg A. Targeting myeloid cells in the tumor sustaining microenvironment. Cell Immunol 2019;343:103713. [PMID: 29129292 DOI: 10.1016/j.cellimm.2017.10.013] [Cited by in Crossref: 43] [Cited by in F6Publishing: 52] [Article Influence: 8.6] [Reference Citation Analysis]
74 Svinka J, Mikulits W, Eferl R. STAT3 in hepatocellular carcinoma: new perspectives. Hepatic Oncol. 2013;1:107-120. [PMID: 30190945 DOI: 10.2217/hep.13.7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
75 Xu YT, Chen RQ, Lin GB, Fang XL, Yu SJ, Liang XH, Zhang R. Defining the regulatory role of programmed cell death 4 in laryngeal squamous cell carcinoma. Biochem Cell Biol 2018;96:522-38. [PMID: 29510060 DOI: 10.1139/bcb-2017-0293] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
76 Paradis V. Benign Liver Tumors: An update. Clinics in Liver Disease 2010;14:719-29. [DOI: 10.1016/j.cld.2010.07.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
77 Fisher DT, Appenheimer MM, Evans SS. The two faces of IL-6 in the tumor microenvironment. Semin Immunol 2014;26:38-47. [PMID: 24602448 DOI: 10.1016/j.smim.2014.01.008] [Cited by in Crossref: 273] [Cited by in F6Publishing: 271] [Article Influence: 34.1] [Reference Citation Analysis]
78 Ploeger C, Waldburger N, Fraas A, Goeppert B, Pusch S, Breuhahn K, Wang XW, Schirmacher P, Roessler S. Chromosome 8p tumor suppressor genes SH2D4A and SORBS3 cooperate to inhibit interleukin-6 signaling in hepatocellular carcinoma. Hepatology 2016;64:828-42. [PMID: 27311882 DOI: 10.1002/hep.28684] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
79 Shanbhogue AK, Prasad SR, Takahashi N, Vikram R, Sahani DV. Recent advances in cytogenetics and molecular biology of adult hepatocellular tumors: Implications for imaging and management. Radiology. 2011;258:673-693. [PMID: 21339346 DOI: 10.1148/radiol.10100376] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 4.2] [Reference Citation Analysis]
80 Agrawal S, Agarwal S, Arnason T, Saini S, Belghiti J. Management of Hepatocellular Adenoma: Recent Advances. Clin Gastroenterol Hepatol. 2015;13:1221-1230. [PMID: 24909909 DOI: 10.1016/j.cgh.2014.05.023] [Cited by in Crossref: 55] [Cited by in F6Publishing: 40] [Article Influence: 6.9] [Reference Citation Analysis]
81 Nault JC, Zucman-Rossi J. Building a bridge between obesity, inflammation and liver carcinogenesis. J Hepatol 2010;53:777-9. [PMID: 20633947 DOI: 10.1016/j.jhep.2010.05.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
82 Sousa CMN, Gadelha PMM, Cartaxo RS, Pedrosa GWH, Honorio RS, Lima JMC, Coelho GR, Coelho CR. Hepatocyte Nuclear Factor 1α-Mutated Hepatocellular Adenomas: An Atypical Presentation. Case Rep Gastroenterol 2017;11:637-42. [PMID: 29282384 DOI: 10.1159/000480376] [Reference Citation Analysis]
83 Fang S, Liu B, Sun Q, Zhao J, Qi H, Li Q. Platelet Factor 4 Inhibits IL-17/Stat3 Pathway via Upregulation of SOCS3 Expression in Melanoma. Inflammation 2014;37:1744-50. [DOI: 10.1007/s10753-014-9903-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
84 Schumacher N, Yan K, Gandraß M, Müller M, Krisp C, Häsler R, Carambia A, Nofer JR, Bernardes JP, Khouja M, Thomsen I, Chalupsky K, Bolik J, Hölscher C, Wunderlich T, Herkel J, Rosenstiel P, Schramm C, Schlüter H, Renné T, Mittrücker HW, Rose-John S, Schmidt-Arras D. Cell-autonomous hepatocyte-specific GP130 signaling is sufficient to trigger a robust innate immune response in mice. J Hepatol 2021;74:407-18. [PMID: 32987028 DOI: 10.1016/j.jhep.2020.09.021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
85 Simoni-Nieves A, Salas-Silva S, Chávez-Rodríguez L, Escobedo-Calvario A, Desoteux M, Bucio L, Souza V, Miranda-Labra RU, Muñoz-Espinosa LE, Coulouarn C, Gutiérrez-Ruiz MC, Marquardt JU, Gomez-Quiroz LE. The Consumption of Cholesterol-Enriched Diets Conditions the Development of a Subtype of HCC with High Aggressiveness and Poor Prognosis. Cancers (Basel) 2021;13:1721. [PMID: 33917315 DOI: 10.3390/cancers13071721] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
86 Drucker C, Gewiese J, Malchow S, Scheller J, Rose-John S. Impact of interleukin-6 classic- and trans-signaling on liver damage and regeneration. J Autoimmun. 2010;34:29-37. [PMID: 19717281 DOI: 10.1016/j.jaut.2009.08.003] [Cited by in Crossref: 55] [Cited by in F6Publishing: 57] [Article Influence: 4.2] [Reference Citation Analysis]
87 Chalaris A, Schmidt-Arras D, Yamamoto K, Rose-John S. Interleukin-6 trans-signaling and colonic cancer associated with inflammatory bowel disease. Dig Dis. 2012;30:492-499. [PMID: 23108305 DOI: 10.1159/000341698] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
88 Pelletier L, Rebouissou S, Vignjevic D, Bioulac-Sage P, Zucman-Rossi J. HNF1α inhibition triggers epithelial-mesenchymal transition in human liver cancer cell lines. BMC Cancer 2011;11:427. [PMID: 21975049 DOI: 10.1186/1471-2407-11-427] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
89 Shafizadeh N, Genrich G, Ferrell L, Kakar S. Hepatocellular adenomas in a large community population, 2000 to 2010: reclassification per current World Health Organization classification and results of long-term follow-up. Human Pathology 2014;45:976-83. [DOI: 10.1016/j.humpath.2013.12.011] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
90 Lepiller Q, Abbas W, Kumar A, Tripathy MK, Herbein G. HCMV activates the IL-6-JAK-STAT3 axis in HepG2 cells and primary human hepatocytes. PLoS One 2013;8:e59591. [PMID: 23555719 DOI: 10.1371/journal.pone.0059591] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 4.2] [Reference Citation Analysis]
91 Bioulac-Sage P, Balabaud C, Zucman-Rossi J. Will the pathomolecular classification of hepatocellular adenomas improve their clinical management? J Hepatol. 2011;55:8-10. [PMID: 21300118 DOI: 10.1016/j.jhep.2011.01.016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
92 Pilati C, Letouzé E, Nault JC, Imbeaud S, Boulai A, Calderaro J, Poussin K, Franconi A, Couchy G, Morcrette G. Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation. Cancer Cell. 2014;25:428-441. [PMID: 24735922 DOI: 10.1016/j.ccr.2014.03.005] [Cited by in Crossref: 178] [Cited by in F6Publishing: 147] [Article Influence: 22.3] [Reference Citation Analysis]
93 Taniguchi K, Karin M. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Seminars in Immunology. 2014;26:54-74. [PMID: 24552665 DOI: 10.1016/j.smim.2014.01.001] [Cited by in Crossref: 319] [Cited by in F6Publishing: 319] [Article Influence: 39.9] [Reference Citation Analysis]
94 Lee C, Cheung ST. STAT3: An Emerging Therapeutic Target for Hepatocellular Carcinoma. Cancers (Basel). 2019;11. [PMID: 31731457 DOI: 10.3390/cancers11111646] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
95 Nakagawa H, Maeda S. Inflammation- and stress-related signaling pathways in hepatocarcinogenesis. World J Gastroenterol 2012; 18(31): 4071-4081 [PMID: 22919237 DOI: 10.3748/wjg.v18.i31.4071] [Cited by in CrossRef: 88] [Cited by in F6Publishing: 80] [Article Influence: 8.8] [Reference Citation Analysis]
96 Henriet E, Abou Hammoud A, Dupuy J, Dartigues B, Ezzoukry Z, Dugot-senant N, Leste-lasserre T, Pallares-lupon N, Nikolski M, Le Bail B, Blanc J, Balabaud C, Bioulac-sage P, Raymond A, Saltel F. Argininosuccinate synthase 1 (ASS1): A marker of unclassified hepatocellular adenoma and high bleeding risk: Henriet, Abou Hammoud, et al. Hepatology 2017;66:2016-28. [DOI: 10.1002/hep.29336] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 9.6] [Reference Citation Analysis]
97 Sabaawy HE, Ryan BM, Khiabanian H, Pine SR. JAK/STAT of all trades: Linking inflammation with cancer development, tumor progression, and therapy resistance. Carcinogenesis 2021:bgab075. [PMID: 34415330 DOI: 10.1093/carcin/bgab075] [Reference Citation Analysis]
98 Nault J, Ningarhari M, Rebouissou S, Zucman-rossi J. The role of telomeres and telomerase in cirrhosis and liver cancer. Nat Rev Gastroenterol Hepatol 2019;16:544-58. [DOI: 10.1038/s41575-019-0165-3] [Cited by in Crossref: 55] [Cited by in F6Publishing: 58] [Article Influence: 18.3] [Reference Citation Analysis]
99 Buchert M, Burns CJ, Ernst M. Targeting JAK kinase in solid tumors: emerging opportunities and challenges. Oncogene 2016;35:939-51. [DOI: 10.1038/onc.2015.150] [Cited by in Crossref: 129] [Cited by in F6Publishing: 123] [Article Influence: 18.4] [Reference Citation Analysis]
100 Howlett M, Menheniott TR, Judd LM, Giraud AS. Cytokine signalling via gp130 in gastric cancer. Biochim Biophys Acta 2009;1793:1623-33. [PMID: 19665497 DOI: 10.1016/j.bbamcr.2009.07.009] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 3.3] [Reference Citation Analysis]
101 Laumonier H, Frulio N, Laurent C, Balabaud C, Zucman-Rossi J, Bioulac-Sage P. Focal nodular hyperplasia with major sinusoidal dilatation: a misleading entity. BMJ Case Rep 2010;2010:bcr0920103311. [PMID: 22798311 DOI: 10.1136/bcr.09.2010.3311] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
102 Hirano T. IL-6 in inflammation, autoimmunity and cancer. Int Immunol 2021;33:127-48. [PMID: 33337480 DOI: 10.1093/intimm/dxaa078] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 18.0] [Reference Citation Analysis]
103 Scheller J, Engelowski E, Moll JM, Floss DM. Immunoreceptor Engineering and Synthetic Cytokine Signaling for Therapeutics. Trends in Immunology 2019;40:258-72. [DOI: 10.1016/j.it.2019.01.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
104 Bioulac-Sage P, Laumonier H, Couchy G, Le Bail B, Sa Cunha A, Rullier A, Laurent C, Blanc JF, Cubel G, Trillaud H, Zucman-Rossi J, Balabaud C, Saric J. Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology 2009;50:481-9. [PMID: 19585623 DOI: 10.1002/hep.22995] [Cited by in Crossref: 317] [Cited by in F6Publishing: 233] [Article Influence: 24.4] [Reference Citation Analysis]
105 Schmidt-Arras D, Böhmer FD. Mislocalisation of Activated Receptor Tyrosine Kinases - Challenges for Cancer Therapy. Trends Mol Med 2020;26:833-47. [PMID: 32593582 DOI: 10.1016/j.molmed.2020.06.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
106 Wu X, Cao Y, Xiao H, Li C, Lin J. Bazedoxifene as a Novel GP130 Inhibitor for Pancreatic Cancer Therapy. Mol Cancer Ther 2016;15:2609-19. [PMID: 27535971 DOI: 10.1158/1535-7163.MCT-15-0921] [Cited by in Crossref: 39] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
107 Bioulac-sage P, Balabaud C, Zucman-rossi J. Apport de l’immunohistochimie dans le diagnostic des tumeurs hépatocellulaires bénignes. Annales de Pathologie 2010;30:439-47. [DOI: 10.1016/j.annpat.2010.10.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
108 Musteanu M, Blaas L, Mair M, Schlederer M, Bilban M, Tauber S, Esterbauer H, Mueller M, Casanova E, Kenner L, Poli V, Eferl R. Stat3 is a negative regulator of intestinal tumor progression in Apc(Min) mice. Gastroenterology. 2010;138:1003-11.e1-5. [PMID: 19962983 DOI: 10.1053/j.gastro.2009.11.049] [Cited by in Crossref: 111] [Cited by in F6Publishing: 108] [Article Influence: 8.5] [Reference Citation Analysis]
109 Rinis N, Küster A, Schmitz-Van de Leur H, Mohr A, Müller-Newen G. Intracellular signaling prevents effective blockade of oncogenic gp130 mutants by neutralizing antibodies. Cell Commun Signal. 2014;12:14. [PMID: 24612692 DOI: 10.1186/1478-811x-12-14] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
110 Xu J, Chen Y, Yang R, Zhou T, Ke W, Si Y, Yang S, Zhang T, Liu X, Zhang L, Xiang K, Guo Y, Liu Y. Cucurbitacin B inhibits gastric cancer progression by suppressing STAT3 activity. Arch Biochem Biophys 2020;684:108314. [PMID: 32088220 DOI: 10.1016/j.abb.2020.108314] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
111 Rebouissou S, Franconi A, Calderaro J, Letouzé E, Imbeaud S, Pilati C, Nault J, Couchy G, Laurent A, Balabaud C, Bioulac‐sage P, Zucman‐rossi J. Genotype‐phenotype correlation of CTNNB1 mutations reveals different ß‐catenin activity associated with liver tumor progression. Hepatology 2016;64:2047-61. [DOI: 10.1002/hep.28638] [Cited by in Crossref: 127] [Cited by in F6Publishing: 123] [Article Influence: 21.2] [Reference Citation Analysis]
112 Pelletier L, Rebouissou S, Paris A, Rathahao-paris E, Perdu E, Bioulac-sage P, Imbeaud S, Zucman-rossi J. Loss of hepatocyte nuclear factor 1α function in human hepatocellular adenomas leads to aberrant activation of signaling pathways involved in tumorigenesis. Hepatology 2010;51:557-66. [DOI: 10.1002/hep.23362] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 3.7] [Reference Citation Analysis]
113 Ronot M, Bahrami S, Calderaro J, Valla DC, Bedossa P, Belghiti J, Vilgrain V, Paradis V. Hepatocellular adenomas: accuracy of magnetic resonance imaging and liver biopsy in subtype classification. Hepatology. 2011;53:1182-1191. [PMID: 21480324 DOI: 10.1002/hep.24147] [Cited by in Crossref: 148] [Cited by in F6Publishing: 124] [Article Influence: 13.5] [Reference Citation Analysis]
114 Balabaud C, Laurent C, Le Bail B, Castain C, Possenti L, Frulio N, Chiche L, Blanc JF, Bioulac-Sage P. Unexpected discovery of small HNF1α-inactivated hepatocellular adenoma in pathological specimens from patients resected for liver tumours. Liver Int 2018;38:1273-9. [PMID: 29265678 DOI: 10.1111/liv.13667] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
115 Choi SYC, Lin D, Gout PW, Collins CC, Xu Y, Wang Y. Lessons from patient-derived xenografts for better in vitro modeling of human cancer. Advanced Drug Delivery Reviews 2014;79-80:222-37. [DOI: 10.1016/j.addr.2014.09.009] [Cited by in Crossref: 110] [Cited by in F6Publishing: 103] [Article Influence: 13.8] [Reference Citation Analysis]
116 Monga SP. Role of Wnt/β-catenin signaling in liver metabolism and cancer. Int J Biochem Cell Biol. 2011;43:1021-1029. [PMID: 19747566 DOI: 10.1016/j.biocel.2009.09.001] [Cited by in Crossref: 100] [Cited by in F6Publishing: 108] [Article Influence: 7.7] [Reference Citation Analysis]
117 Dourthe C, Julien C, Di Tommaso S, Dupuy JW, Dugot-Senant N, Brochard A, Le Bail B, Blanc JF, Chiche L, Balabaud C, Bioulac-Sage P, Saltel F, Raymond AA. Proteomic Profiling of Hepatocellular Adenomas Paves the Way to Diagnostic and Prognostic Approaches. Hepatology 2021. [PMID: 33754354 DOI: 10.1002/hep.31826] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
118 He G, Yu GY, Temkin V, Ogata H, Kuntzen C, Sakurai T, Sieghart W, Peck-Radosavljevic M, Leffert HL, Karin M. Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell. 2010;17:286-297. [PMID: 20227042 DOI: 10.1016/j.ccr.2009.12.048] [Cited by in Crossref: 291] [Cited by in F6Publishing: 286] [Article Influence: 24.3] [Reference Citation Analysis]
119 Clément B, Chêne G, Degos F. A national collection of liver tumours: Lessons learnt from 6 years of biobanking in France. Cancer Letters 2009;286:140-4. [DOI: 10.1016/j.canlet.2009.04.034] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
120 Molares-Vila A, Corbalán-Rivas A, Carnero-Gregorio M, González-Cespón JL, Rodríguez-Cerdeira C. Biomarkers in Glycogen Storage Diseases: An Update. Int J Mol Sci 2021;22:4381. [PMID: 33922238 DOI: 10.3390/ijms22094381] [Reference Citation Analysis]
121 Paradis V. Hepatocellular Adenomas. Surgical Pathology Clinics 2013;6:311-31. [DOI: 10.1016/j.path.2013.03.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
122 Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, Osterreicher CH, Takahashi H, Karin M. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010;140:197-208. [PMID: 20141834 DOI: 10.1016/j.cell.2009.12.052] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
123 Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 2011;1813:878-888. [PMID: 21296109 DOI: 10.1016/j.bbamcr.2011.01.034] [Cited by in Crossref: 1633] [Cited by in F6Publishing: 1623] [Article Influence: 148.5] [Reference Citation Analysis]
124 Beaufrère A, Paradis V. Hepatocellular adenomas: review of pathological and molecular features. Hum Pathol 2021;112:128-37. [PMID: 33307077 DOI: 10.1016/j.humpath.2020.11.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
125 Köhler UA, Böhm F, Rolfs F, Egger M, Hornemann T, Pasparakis M, Weber A, Werner S. NF-κB/RelA and Nrf2 cooperate to maintain hepatocyte integrity and to prevent development of hepatocellular adenoma. J Hepatol 2016;64:94-102. [PMID: 26348541 DOI: 10.1016/j.jhep.2015.08.033] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
126 Lefkowitch JH. Neoplasms and Nodules. Scheuer's Liver Biopsy Interpretation. Elsevier; 2010. pp. 181-231. [DOI: 10.1016/b978-0-7020-3410-7.00017-4] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
127 Kumar M, Zhao X, Wang XW. Molecular carcinogenesis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: one step closer to personalized medicine? Cell Biosci. 2011;1:5. [PMID: 21711594 DOI: 10.1186/2045-3701-1-5] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 5.3] [Reference Citation Analysis]
128 Kirchmeyer M, Servais FA, Hamdorf M, Nazarov PV, Ginolhac A, Halder R, Vallar L, Glanemann M, Rubie C, Lammert F, Kreis S, Behrmann I. Cytokine-mediated modulation of the hepatic miRNome: miR-146b-5p is an IL-6-inducible miRNA with multiple targets. J Leukoc Biol 2018;104:987-1002. [DOI: 10.1002/jlb.ma1217-499rr] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
129 Sasaki M, Nakanuma Y. Overview of hepatocellular adenoma in Japan. Int J Hepatol 2012;2012:648131. [PMID: 22973519 DOI: 10.1155/2012/648131] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
130 Garbers C, Heink S, Korn T, Rose-John S. Interleukin-6: designing specific therapeutics for a complex cytokine. Nat Rev Drug Discov. 2018;17:395-412. [PMID: 29725131 DOI: 10.1038/nrd.2018.45] [Cited by in Crossref: 209] [Cited by in F6Publishing: 197] [Article Influence: 52.3] [Reference Citation Analysis]
131 Shafabakhsh R, Reiter RJ, Davoodabadi A, Asemi Z. Melatonin as a potential inhibitor of colorectal cancer: Molecular mechanisms. J Cell Biochem 2019;120:12216-23. [PMID: 31087705 DOI: 10.1002/jcb.28833] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
132 Rosell R, Bertran-Alamillo J, Molina MA, Taron M. IL-6/gp130/STAT3 signaling axis in cancer and the presence of in-frame gp130 somatic deletions in inflammatory hepatocellular tumors. Future Oncol 2009;5:305-8. [PMID: 19374537 DOI: 10.2217/fon.09.3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
133 Schütt A, Zacharias M, Schneider N, Horn S, Grötzinger J, Rose-john S, Schmidt-arras D. gp130 activation is regulated by D2–D3 interdomain connectivity. Biochemical Journal 2013;450:487-96. [DOI: 10.1042/bj20121660] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
134 Kan Z, Zheng H, Liu X, Li S, Barber TD, Gong Z, Gao H, Hao K, Willard MD, Xu J. Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res. 2013;23:1422-1433. [PMID: 23788652 DOI: 10.1101/gr.154492.113] [Cited by in Crossref: 314] [Cited by in F6Publishing: 310] [Article Influence: 34.9] [Reference Citation Analysis]
135 Gilbert LA, Hemann MT. DNA damage-mediated induction of a chemoresistant niche. Cell. 2010;143:355-366. [PMID: 21029859 DOI: 10.1016/j.cell.2010.09.043] [Cited by in Crossref: 287] [Cited by in F6Publishing: 265] [Article Influence: 23.9] [Reference Citation Analysis]
136 Sethi G, Shanmugam MK, Ramachandran L, Kumar AP, Tergaonkar V. Multifaceted link between cancer and inflammation. Biosci Rep. 2012;32:1-15. [PMID: 21981137 DOI: 10.1042/bsr20100136] [Cited by in Crossref: 209] [Cited by in F6Publishing: 113] [Article Influence: 20.9] [Reference Citation Analysis]
137 Kuraishy A, Karin M, Grivennikov SI. Tumor promotion via injury- and death-induced inflammation. Immunity 2011;35:467-77. [PMID: 22035839 DOI: 10.1016/j.immuni.2011.09.006] [Cited by in Crossref: 182] [Cited by in F6Publishing: 173] [Article Influence: 16.5] [Reference Citation Analysis]
138 Salmiheimo AN, Mustonen HK, Vainionpää SA, Shen Z, Kemppainen EA, Seppänen HE, Puolakkainen PA. Increasing the Inflammatory Competence of Macrophages with IL-6 or with Combination of IL-4 and LPS Restrains the Invasiveness of Pancreatic Cancer Cells. J Cancer 2016;7:42-9. [PMID: 26722359 DOI: 10.7150/jca.12923] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
139 van Malenstein H, van Pelt J, Verslype C. Molecular classification of hepatocellular carcinoma anno 2011. Eur J Cancer. 2011;47:1789-1797. [PMID: 21612914 DOI: 10.1016/j.ejca.2011.04.027] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 5.1] [Reference Citation Analysis]
140 Hummel TM, Ackfeld T, Schönberg M, Ciupka G, Schulz F, Oberdoerster A, Grötzinger J, Scheller J, Floss DM. Synthetic Deletion of the Interleukin 23 Receptor (IL-23R) Stalk Region Led to Autonomous IL-23R Homodimerization and Activation. Mol Cell Biol 2017;37:e00014-17. [PMID: 28630278 DOI: 10.1128/MCB.00014-17] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 2.4] [Reference Citation Analysis]
141 Wang Q, Zhai YY, Dai JH, Li KY, Deng Q, Han ZG. SAMD9L inactivation promotes cell proliferation via facilitating G1-S transition in hepatitis B virus-associated hepatocellular carcinoma. Int J Biol Sci 2014;10:807-16. [PMID: 25076857 DOI: 10.7150/ijbs.9143] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
142 Park SA, Kim LK, Park HM, Kim HJ, Heo TH. Inhibition of GP130/STAT3 and EMT by combined bazedoxifene and paclitaxel treatment in ovarian cancer. Oncol Rep 2022;47:52. [PMID: 35029286 DOI: 10.3892/or.2022.8263] [Reference Citation Analysis]
143 Shafizadeh N, Kakar S. Diagnosis of well-differentiated hepatocellular lesions: role of immunohistochemistry and other ancillary techniques. Adv Anat Pathol. 2011;18:438-445. [PMID: 21993269 DOI: 10.1097/pap.0b013e318234abb4] [Cited by in Crossref: 57] [Cited by in F6Publishing: 7] [Article Influence: 5.7] [Reference Citation Analysis]
144 Nault JC, Fabre M, Couchy G, Pilati C, Jeannot E, Tran Van Nhieu J, Saint-Paul MC, De Muret A, Redon MJ, Buffet C, Salenave S, Balabaud C, Prevot S, Labrune P, Bioulac-Sage P, Scoazec JY, Chanson P, Zucman-Rossi J. GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. J Hepatol. 2012;56:184-191. [PMID: 21835143 DOI: 10.1016/j.jhep.2011.07.018] [Cited by in Crossref: 85] [Cited by in F6Publishing: 83] [Article Influence: 7.7] [Reference Citation Analysis]
145 Choi WT, Ramachandran R, Kakar S. Immunohistochemical approach for the diagnosis of a liver mass on small biopsy specimens. Hum Pathol. 2017;63:1-13. [PMID: 28087475 DOI: 10.1016/j.humpath.2016.12.025] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
146 Monga SP. β-Catenin Signaling and Roles in Liver Homeostasis, Injury, and Tumorigenesis. Gastroenterology 2015;148:1294-310. [PMID: 25747274 DOI: 10.1053/j.gastro.2015.02.056] [Cited by in Crossref: 247] [Cited by in F6Publishing: 238] [Article Influence: 35.3] [Reference Citation Analysis]
147 Lefkowitch JH. Recent developments in liver pathology. Human Pathology 2009;40:445-55. [DOI: 10.1016/j.humpath.2008.12.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
148 Suthaus J, Adam N, Grötzinger J, Scheller J, Rose-john S. Viral Interleukin-6: Structure, pathophysiology and strategies of neutralization. European Journal of Cell Biology 2011;90:495-504. [DOI: 10.1016/j.ejcb.2010.10.016] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
149 Lee HK, Seo IA, Shin YK, Park JW, Suh DJ, Park HT. Capsaicin inhibits the IL-6/STAT3 pathway by depleting intracellular gp130 pools through endoplasmic reticulum stress. Biochemical and Biophysical Research Communications 2009;382:445-50. [DOI: 10.1016/j.bbrc.2009.03.046] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
150 Silver JS, Stumhofer JS, Passos S, Ernst M, Hunter CA. IL-6 mediates the susceptibility of glycoprotein 130 hypermorphs to Toxoplasma gondii. J Immunol 2011;187:350-60. [PMID: 21606248 DOI: 10.4049/jimmunol.1004144] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
151 Monga SP. Role of Wnt/β-catenin signaling in liver metabolism and cancer. Int J Biochem Cell Biol. 2011;43:1021-1029. [PMID: 19747566 DOI: 10.1016/j.biocel.2009.09.001s1357-2725(09)00244-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
152 Ding Y, Shao J, Shi T, Yu H, Wang X, Chi H, Wang X. Leukemia inhibitory factor receptor homodimerization mediated by acetylation of extracellular lysine promotes prostate cancer progression through the PDPK1/AKT/GCN5 axis. Clin Transl Med 2022;12:e676. [PMID: 35172032 DOI: 10.1002/ctm2.676] [Reference Citation Analysis]
153 Hilfiker-Kleiner D, Shukla P, Klein G, Schaefer A, Stapel B, Hoch M, Müller W, Scherr M, Theilmeier G, Ernst M, Hilfiker A, Drexler H. Continuous glycoprotein-130-mediated signal transducer and activator of transcription-3 activation promotes inflammation, left ventricular rupture, and adverse outcome in subacute myocardial infarction. Circulation 2010;122:145-55. [PMID: 20585009 DOI: 10.1161/CIRCULATIONAHA.109.933127] [Cited by in Crossref: 108] [Cited by in F6Publishing: 64] [Article Influence: 9.0] [Reference Citation Analysis]
154 Ferrell LD, Kakar S, Terracciano LM, Wee A. Tumours and Tumour-like Lesions of the Liver. Macsween's Pathology of the Liver. Elsevier; 2018. pp. 780-879. [DOI: 10.1016/b978-0-7020-6697-9.00013-3] [Cited by in Crossref: 5] [Article Influence: 1.3] [Reference Citation Analysis]
155 Levine RL. JAK-mutant myeloproliferative neoplasms. Curr Top Microbiol Immunol 2012;355:119-33. [PMID: 21823028 DOI: 10.1007/82_2011_170] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 0.3] [Reference Citation Analysis]
156 Dharmana H, Saravana-bawan S, Girgis S, Low G. Hepatocellular adenoma: imaging review of the various molecular subtypes. Clinical Radiology 2017;72:276-85. [DOI: 10.1016/j.crad.2016.12.020] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 3.2] [Reference Citation Analysis]
157 Bioulac-Sage P, Laumonier H, Cubel G, Rossi JZ, Balabaud C. Hepatic resection for inflammatory hepatocellular adenomas: pathological identification of micronodules expressing inflammatory proteins. Liver Int. 2010;30:149-154. [PMID: 19845852 DOI: 10.1111/j.1478-3231.2009.02098.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
158 Jones SA, Jenkins BJ. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol 2018;18:773-89. [DOI: 10.1038/s41577-018-0066-7] [Cited by in Crossref: 251] [Cited by in F6Publishing: 243] [Article Influence: 62.8] [Reference Citation Analysis]
159 Sommer J, Effenberger T, Volpi E, Waetzig GH, Bernhardt M, Suthaus J, Garbers C, Rose-John S, Floss DM, Scheller J. Constitutively active mutant gp130 receptor protein from inflammatory hepatocellular adenoma is inhibited by an anti-gp130 antibody that specifically neutralizes interleukin 11 signaling. J Biol Chem 2012;287:13743-51. [PMID: 22523320 DOI: 10.1074/jbc.M111.349167] [Cited by in Crossref: 9] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
160 Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol 2015;16:448-57. [DOI: 10.1038/ni.3153] [Cited by in Crossref: 1092] [Cited by in F6Publishing: 1010] [Article Influence: 156.0] [Reference Citation Analysis]
161 Tan Z, Xue H, Sun Y, Zhang C, Song Y, Qi Y. The Role of Tumor Inflammatory Microenvironment in Lung Cancer. Front Pharmacol 2021;12:688625. [PMID: 34079469 DOI: 10.3389/fphar.2021.688625] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
162 Tao Y, Ruan J, Yeh SH, Lu X, Wang Y, Zhai W, Cai J, Ling S, Gong Q, Chong Z. Rapid growth of a hepatocellular carcinoma and the driving mutations revealed by cell-population genetic analysis of whole-genome data. Proc Natl Acad Sci USA. 2011;108:12042-12047. [PMID: 21730188 DOI: 10.1073/pnas.1108715108] [Cited by in Crossref: 100] [Cited by in F6Publishing: 95] [Article Influence: 9.1] [Reference Citation Analysis]
163 Joseph NM, Ferrell LD, Jain D, Torbenson MS, Wu TT, Yeh MM, Kakar S. Diagnostic utility and limitations of glutamine synthetase and serum amyloid-associated protein immunohistochemistry in the distinction of focal nodular hyperplasia and inflammatory hepatocellular adenoma. Mod Pathol 2014;27:62-72. [PMID: 23807780 DOI: 10.1038/modpathol.2013.114] [Cited by in Crossref: 51] [Cited by in F6Publishing: 39] [Article Influence: 5.7] [Reference Citation Analysis]
164 Engelowski E, Schneider A, Franke M, Xu H, Clemen R, Lang A, Baran P, Binsch C, Knebel B, Al-Hasani H, Moll JM, Floß DM, Lang PA, Scheller J. Synthetic cytokine receptors transmit biological signals using artificial ligands. Nat Commun 2018;9:2034. [PMID: 29789554 DOI: 10.1038/s41467-018-04454-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
165 Suthaus J, Tillmann A, Lorenzen I, Bulanova E, Rose-John S, Scheller J. Forced homo- and heterodimerization of all gp130-type receptor complexes leads to constitutive ligand-independent signaling and cytokine-independent growth. Mol Biol Cell 2010;21:2797-807. [PMID: 20554759 DOI: 10.1091/mbc.E10-03-0240] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.6] [Reference Citation Analysis]
166 Gao H, Jiang Q, Han Y, Peng J, Wang C. Hispidulin Potentiates the Antitumor Effect of Sunitinib Against Human Renal Cell Carcinoma in Laboratory Models. Cell Biochem Biophys 2015;71:757-64. [DOI: 10.1007/s12013-014-0260-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
167 Margolskee E, Bao F, de Gonzalez AK, Moreira RK, Lagana S, Sireci AN, Sepulveda AR, Remotti H, Lefkowitch JH, Salomao M. Hepatocellular adenoma classification: a comparative evaluation of immunohistochemistry and targeted mutational analysis. Diagn Pathol. 2016;11:27. [PMID: 26961851 DOI: 10.1186/s13000-016-0475-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
168 Calderaro J, Labrune P, Morcrette G, Rebouissou S, Franco D, Prévot S, Quaglia A, Bedossa P, Libbrecht L, Terracciano L. Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I. J Hepatol. 2013;58:350-357. [PMID: 23046672 DOI: 10.1016/j.jhep.2012.09.030] [Cited by in Crossref: 105] [Cited by in F6Publishing: 94] [Article Influence: 10.5] [Reference Citation Analysis]
169 Nault JC, Couchy G, Caruso S, Meunier L, Caruana L, Letouzé E, Rebouissou S, Paradis V, Calderaro J, Zucman-Rossi J. Argininosuccinate synthase 1 and periportal gene expression in sonic hedgehog hepatocellular adenomas. Hepatology 2018;68:964-76. [PMID: 29572896 DOI: 10.1002/hep.29884] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
170 Crescenzo R, Abate F, Lasorsa E, Tabbo' F, Gaudiano M, Chiesa N, Di Giacomo F, Spaccarotella E, Barbarossa L, Ercole E, Todaro M, Boi M, Acquaviva A, Ficarra E, Novero D, Rinaldi A, Tousseyn T, Rosenwald A, Kenner L, Cerroni L, Tzankov A, Ponzoni M, Paulli M, Weisenburger D, Chan WC, Iqbal J, Piris MA, Zamo' A, Ciardullo C, Rossi D, Gaidano G, Pileri S, Tiacci E, Falini B, Shultz LD, Mevellec L, Vialard JE, Piva R, Bertoni F, Rabadan R, Inghirami G; European T-Cell Lymphoma Study Group, T-Cell Project: Prospective Collection of Data in Patients with Peripheral T-Cell Lymphoma and the AIRC 5xMille Consortium “Genetics-Driven Targeted Management of Lymphoid Malignancies”. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell 2015;27:516-32. [PMID: 25873174 DOI: 10.1016/j.ccell.2015.03.006] [Cited by in Crossref: 247] [Cited by in F6Publishing: 241] [Article Influence: 35.3] [Reference Citation Analysis]
171 Agostini CH, Ribeiro OD, Fernandes A, Caroli-bottino A, Pannain VL. Relevance of morphological features for hepatocellular adenoma classification in pathology practice. Surg Exp Pathol 2020;3. [DOI: 10.1186/s42047-020-00061-4] [Reference Citation Analysis]
172 Okitsu K, Kanda T, Imazeki F, Yonemitsu Y, Ray RB, Chang C, Yokosuka O. Involvement of interleukin-6 and androgen receptor signaling in pancreatic cancer. Genes Cancer. 2010;1:859-867. [PMID: 21779469 DOI: 10.1177/1947601910383417] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 2.9] [Reference Citation Analysis]
173 He G, Yu GY, Temkin V, Ogata H, Kuntzen C, Sakurai T, Sieghart W, Peck-Radosavljevic M, Leffert HL, Karin M. Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell 2010;17:286-97. [PMID: 20227042 DOI: 10.1016/j.ccr.2009.12.048] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
174 Sasaki M, Yoneda N, Sawai Y, Imai Y, Kondo F, Fukusato T, Yoshikawa S, Kobayashi S, Sato Y, Matsui O. Clinicopathological characteristics of serum amyloid A-positive hepatocellular neoplasms/nodules arising in alcoholic cirrhosis. Histopathology. 2015;66:836-845. [PMID: 25318388 DOI: 10.1111/his.12588] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
175 Tran Cao HS, Marcal LP, Mason MC, Yedururi S, Joechle K, Wei SH, Vauthey J. Benign hepatic incidentalomas. Current Problems in Surgery 2019;56:100642. [DOI: 10.1067/j.cpsurg.2019.05.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
176 Miyakoshi M, Yamamoto M, Tanaka H, Ogawa K. Serine 727 phosphorylation of STAT3: an early change in mouse hepatocarcinogenesis induced by neonatal treatment with diethylnitrosamine. Mol Carcinog 2014;53:67-76. [PMID: 22911886 DOI: 10.1002/mc.21949] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
177 Mohr A, Chatain N, Domoszlai T, Rinis N, Sommerauer M, Vogt M, Müller-Newen G. Dynamics and non-canonical aspects of JAK/STAT signalling. Eur J Cell Biol 2012;91:524-32. [PMID: 22018664 DOI: 10.1016/j.ejcb.2011.09.005] [Cited by in Crossref: 62] [Cited by in F6Publishing: 65] [Article Influence: 5.6] [Reference Citation Analysis]
178 Assié G, Guillaud-bataille M, Ragazzon B, Bertagna X, Bertherat J, Clauser E. The pathophysiology, diagnosis and prognosis of adrenocortical tumors revisited by transcriptome analyses. Trends in Endocrinology & Metabolism 2010;21:325-34. [DOI: 10.1016/j.tem.2009.12.009] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
179 Murakami M, Hirano T. A four-step model for the IL-6 amplifier, a regulator of chronic inflammations in tissue-specific MHC class II-associated autoimmune diseases. Front Immunol 2011;2:22. [PMID: 22566812 DOI: 10.3389/fimmu.2011.00022] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
180 Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, Calderaro J, Bioulac-Sage P, Letexier M, Degos F, Clément B, Balabaud C, Chevet E, Laurent A, Couchy G, Letouzé E, Calvo F, Zucman-Rossi J. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet 2012;44:694-8. [PMID: 22561517 DOI: 10.1038/ng.2256] [Cited by in Crossref: 847] [Cited by in F6Publishing: 831] [Article Influence: 84.7] [Reference Citation Analysis]
181 Husainy MA, Sayyed F, Peddu P. Typical and atypical benign liver lesions: A review. Clin Imaging 2017;44:79-91. [PMID: 28486156 DOI: 10.1016/j.clinimag.2017.05.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
182 Chen J, Liu RY, Yang L, Zhao J, Zhao X, Lu D, Yi N, Han B, Chen XF, Zhang K, He J, Lei Z, Zhou Y, Pasche B, Li X, Zhang HT. A two-SNP IL-6 promoter haplotype is associated with increased lung cancer risk. J Cancer Res Clin Oncol 2013;139:231-42. [PMID: 23052692 DOI: 10.1007/s00432-012-1314-z] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
183 Poussin K, Pilati C, Couchy G, Calderaro J, Bioulac-Sage P, Bacq Y, Paradis V, Leteurtre E, Sturm N, Ramos J. Biochemical and functional analyses of gp130 mutants unveil JAK1 as a novel therapeutic target in human inflammatory hepatocellular adenoma. Oncoimmunology. 2013;2:e27090. [PMID: 24501689 DOI: 10.4161/onci.27090] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
184 Becht E, Giraldo NA, Germain C, de Reyniès A, Laurent-puig P, Zucman-rossi J, Dieu-nosjean M, Sautès-fridman C, Fridman WH. Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers. Tumor Immunology. Elsevier; 2016. pp. 95-190. [DOI: 10.1016/bs.ai.2015.12.002] [Cited by in Crossref: 102] [Cited by in F6Publishing: 96] [Article Influence: 17.0] [Reference Citation Analysis]
185 Rajala HL, Porkka K, Maciejewski JP, Loughran TP Jr, Mustjoki S. Uncovering the pathogenesis of large granular lymphocytic leukemia-novel STAT3 and STAT5b mutations. Ann Med 2014;46:114-22. [PMID: 24512550 DOI: 10.3109/07853890.2014.882105] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 5.8] [Reference Citation Analysis]
186 Larson BK, Guindi M. A Limited Immunohistochemical Panel Can Subtype Hepatocellular Adenomas for Routine Practice. Am J Clin Pathol 2017;147:557-70. [PMID: 28472207 DOI: 10.1093/ajcp/aqx010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
187 Jones SA, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest 2011;121:3375-83. [PMID: 21881215 DOI: 10.1172/JCI57158] [Cited by in Crossref: 441] [Cited by in F6Publishing: 233] [Article Influence: 40.1] [Reference Citation Analysis]
188 Chun YS, Calderaro J, Zucman-rossi J. Synchronous hepatocellular carcinoma and Castleman's disease: The role of the interleukin-6-signaling pathway. Hepatology 2012;56:392-3. [DOI: 10.1002/hep.25857] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
189 Sasaki M, Yoneda N, Kitamura S, Sato Y, Nakanuma Y. Characterization of hepatocellular adenoma based on the phenotypic classification: The Kanazawa experience. Hepatol Res. 2011;41:982-988. [PMID: 21883740 DOI: 10.1111/j.1872-034x.2011.00851.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 18] [Article Influence: 3.9] [Reference Citation Analysis]
190 Chun YS, House MG, Kaur H, Loyer EM, Paradis V, Vauthey JN. SSAT/AHPBA joint symposium on evaluation and treatment of benign liver lesions. J Gastrointest Surg 2013;17:636-44. [PMID: 23377783 DOI: 10.1007/s11605-013-2153-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
191 Bioulac-Sage P, Sempoux C, Balabaud C. Hepatocellular adenoma: Classification, variants and clinical relevance. Semin Diagn Pathol. 2017;34:112-125. [PMID: 28131467 DOI: 10.1053/j.semdp.2016.12.007] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 7.3] [Reference Citation Analysis]
192 Cui X, Hu ZP, Li Z, Gao PJ, Zhu JY. Overexpression of chaperonin containing TCP1, subunit 3 predicts poor prognosis in hepatocellular carcinoma. World J Gastroenterol 2015; 21(28): 8588-8604 [PMID: 26229401 DOI: 10.3748/wjg.v21.i28.8588] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
193 Nakagawa H, Fujita M, Fujimoto A. Genome sequencing analysis of liver cancer for precision medicine. Semin Cancer Biol 2019;55:120-7. [PMID: 29605648 DOI: 10.1016/j.semcancer.2018.03.004] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
194 Laumonier H, Cailliez H, Balabaud C, Possenti L, Zucman-Rossi J, Bioulac-Sage P, Trillaud H. Role of contrast-enhanced sonography in differentiation of subtypes of hepatocellular adenoma: correlation with MRI findings. AJR Am J Roentgenol. 2012;199:341-348. [PMID: 22826395 DOI: 10.2214/ajr.11.7046] [Cited by in Crossref: 44] [Cited by in F6Publishing: 17] [Article Influence: 4.4] [Reference Citation Analysis]
195 Takahashi A, Tokita H, Takahashi K, Takeoka T, Murayama K, Tomotsune D, Ohira M, Iwamatsu A, Ohara K, Yazaki K, Koda T, Nakagawara A, Tani K. A novel potent tumour promoter aberrantly overexpressed in most human cancers. Sci Rep 2011;1:15. [PMID: 22355534 DOI: 10.1038/srep00015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
196 Murakami M, Kamimura D, Hirano T. Pleiotropy and Specificity: Insights from the Interleukin 6 Family of Cytokines. Immunity 2019;50:812-31. [DOI: 10.1016/j.immuni.2019.03.027] [Cited by in Crossref: 127] [Cited by in F6Publishing: 125] [Article Influence: 42.3] [Reference Citation Analysis]
197 Chen G, Shi Y, Zhang Y, Sun J. CircRNA_100782 regulates pancreatic carcinoma proliferation through the IL6-STAT3 pathway. Onco Targets Ther 2017;10:5783-94. [PMID: 29255366 DOI: 10.2147/OTT.S150678] [Cited by in Crossref: 80] [Cited by in F6Publishing: 48] [Article Influence: 16.0] [Reference Citation Analysis]
198 Han J, van den Heuvel MC, Kusano H, de Jong KP, Gouw AS. How normal is the liver in which the inflammatory type hepatocellular adenoma develops? Int J Hepatol 2012;2012:805621. [PMID: 23024866 DOI: 10.1155/2012/805621] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
199 Slinger E, Langemeijer E, Siderius M, Vischer HF, Smit MJ. Herpesvirus-encoded GPCRs rewire cellular signaling. Molecular and Cellular Endocrinology 2011;331:179-84. [DOI: 10.1016/j.mce.2010.04.007] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
200 Agnello F, Ronot M, Valla DC, Sinkus R, Van Beers BE, Vilgrain V. High-b-value diffusion-weighted MR imaging of benign hepatocellular lesions: quantitative and qualitative analysis. Radiology. 2012;262:511-519. [PMID: 22143926 DOI: 10.1148/radiol.11110922] [Cited by in Crossref: 63] [Cited by in F6Publishing: 48] [Article Influence: 5.7] [Reference Citation Analysis]
201 Anson M, Crain-Denoyelle AM, Baud V, Chereau F, Gougelet A, Terris B, Yamagoe S, Colnot S, Viguier M, Perret C. Oncogenic β-catenin triggers an inflammatory response that determines the aggressiveness of hepatocellular carcinoma in mice. J Clin Invest. 2012;122:586-599. [PMID: 22251704 DOI: 10.1172/jci43937] [Cited by in Crossref: 122] [Cited by in F6Publishing: 77] [Article Influence: 12.2] [Reference Citation Analysis]
202 Schirmacher P, Longerich T. Hochdifferenzierte Lebertumoren: Neue Entwicklungen und ihre diagnostische Relevanz. Pathologe 2009;30:200-6. [DOI: 10.1007/s00292-009-1214-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
203 Clapéron A, Mergey M, Fouassier L. Roles of the scaffolding proteins NHERF in liver biology. Clin Res Hepatol Gastroenterol 2011;35:176-81. [PMID: 21501979 DOI: 10.1016/j.clinre.2010.11.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
204 Schmidt-Arras D, Rose-John S. IL-6 pathway in the liver: From physiopathology to therapy. J Hepatol. 2016;64:1403-1415. [PMID: 26867490 DOI: 10.1016/j.jhep.2016.02.004] [Cited by in Crossref: 305] [Cited by in F6Publishing: 300] [Article Influence: 50.8] [Reference Citation Analysis]
205 Liu H, Zhao Q, Jin G, Qian Y, Gu Y, Dong H, Lu X, Cong W, Wu M. Unique genetic alterations and clinicopathological features of hepatocellular adenoma in Chinese population. Pathology - Research and Practice 2015;211:918-24. [DOI: 10.1016/j.prp.2015.09.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
206 Liu TC, Vachharajani N, Chapman WC, Brunt EM. Noncirrhotic hepatocellular carcinoma: derivation from hepatocellular adenoma? Clinicopathologic analysis. Mod Pathol 2014;27:420-32. [PMID: 24051694 DOI: 10.1038/modpathol.2013.148] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
207 Yoneda N, Matsui O, Kitao A, Kozaka K, Kobayashi S, Sasaki M, Yoshida K, Inoue D, Minami T, Gabata T. Benign Hepatocellular Nodules: Hepatobiliary Phase of Gadoxetic Acid-enhanced MR Imaging Based on Molecular Background. Radiographics 2016;36:2010-27. [PMID: 27740898 DOI: 10.1148/rg.2016160037] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 7.5] [Reference Citation Analysis]
208 van Aalten SM, Verheij J, Terkivatan T, Dwarkasing RS, de Man RA, Ijzermans JN. Validation of a liver adenoma classification system in a tertiary referral centre: implications for clinical practice. J Hepatol. 2011;55:120-125. [PMID: 21145863 DOI: 10.1016/j.jhep.2010.10.030] [Cited by in Crossref: 74] [Cited by in F6Publishing: 59] [Article Influence: 6.2] [Reference Citation Analysis]
209 Zheng JX, Zeng Z, Zheng YY, Yin SJ, Zhang DY, Yu YY, Wang F. Role of hepatitis B virus base core and precore/core promoter mutations on hepatocellular carcinoma in untreated older genotype C Chinese patients. J Viral Hepat. 2011;18:e423-e431. [PMID: 21914059 DOI: 10.1111/j.1365-2893.2011.01458.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
210 Bioulac-Sage P, Balabaud C, Chevet E. Vicious cycle in liver carcinogenesis: an epigenetic mirage. Clin Res Hepatol Gastroenterol 2012;36:200-1. [PMID: 22405836 DOI: 10.1016/j.clinre.2012.01.006] [Reference Citation Analysis]
211 Schmidt-Arras D, Galun E, Rose-John S. The two facets of gp130 signalling in liver tumorigenesis. Semin Immunopathol 2021. [PMID: 34047814 DOI: 10.1007/s00281-021-00861-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
212 Rose-John S. Interleukin-6 Family Cytokines. Cold Spring Harb Perspect Biol 2018;10:a028415. [PMID: 28620096 DOI: 10.1101/cshperspect.a028415] [Cited by in Crossref: 170] [Cited by in F6Publishing: 161] [Article Influence: 42.5] [Reference Citation Analysis]
213 Gilbert LA, Hemann MT. Chemotherapeutic resistance: surviving stressful situations. Cancer Res 2011;71:5062-6. [PMID: 21771909 DOI: 10.1158/0008-5472.CAN-11-0277] [Cited by in Crossref: 40] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
214 Bise S, Frulio N, Hocquelet A, Alberti N, Blanc JF, Laurent C, Laumonier H, Balabaud C, Bioulac-Sage P, Trillaud H. New MRI features improve subtype classification of hepatocellular adenoma. Eur Radiol 2019;29:2436-47. [PMID: 30523457 DOI: 10.1007/s00330-018-5784-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
215 Korneev KV, Atretkhany KN, Drutskaya MS, Grivennikov SI, Kuprash DV, Nedospasov SA. TLR-signaling and proinflammatory cytokines as drivers of tumorigenesis. Cytokine 2017;89:127-35. [DOI: 10.1016/j.cyto.2016.01.021] [Cited by in Crossref: 74] [Cited by in F6Publishing: 69] [Article Influence: 14.8] [Reference Citation Analysis]
216 Garbers C, Hermanns HM, Schaper F, Müller-Newen G, Grötzinger J, Rose-John S, Scheller J. Plasticity and cross-talk of interleukin 6-type cytokines. Cytokine Growth Factor Rev. 2012;23:85-97. [PMID: 22595692 DOI: 10.1016/j.cytogfr.2012.04.001] [Cited by in Crossref: 224] [Cited by in F6Publishing: 217] [Article Influence: 22.4] [Reference Citation Analysis]
217 Bioulac-Sage P, Balabaud C, Zucman-Rossi J. Focal nodular hyperplasia, hepatocellular adenomas: past, present, future. Gastroenterol Clin Biol. 2010;34:355-358. [PMID: 20537479 DOI: 10.1016/j.gcb.2010.03.014] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
218 Marquardt JU, Thorgeirsson SS. Next-generation genomic profiling of hepatocellular adenomas: a new era of individualized patient care. Cancer Cell 2014;25:409-11. [PMID: 24735920 DOI: 10.1016/j.ccr.2014.03.032] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
219 Groner B. Determinants of the extent and duration of STAT3 signaling. JAKSTAT 2012;1:211-5. [PMID: 24058775 DOI: 10.4161/jkst.21469] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
220 Liao YT, Jeng YM, Lee YH, Tsai MK, Hu RH, Ho MC. The occurrence of primary hepatic adenoma in deceased donor renal transplant recipient. Int Braz J Urol 2014;40:118-22. [PMID: 24642158 DOI: 10.1590/S1677-5538.IBJU.2014.01.17] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
221 Zucman-rossi J, Villanueva A, Nault J, Llovet JM. Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. Gastroenterology 2015;149:1226-1239.e4. [DOI: 10.1053/j.gastro.2015.05.061] [Cited by in Crossref: 531] [Cited by in F6Publishing: 530] [Article Influence: 75.9] [Reference Citation Analysis]
222 Wang H, Lafdil F, Kong X, Gao B. Signal transducer and activator of transcription 3 in liver diseases: a novel therapeutic target. Int J Biol Sci. 2011;7:536-550. [PMID: 21552420 DOI: 10.7150/ijbs.7.536] [Cited by in Crossref: 164] [Cited by in F6Publishing: 169] [Article Influence: 14.9] [Reference Citation Analysis]
223 Grivennikov SI, Karin M. Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev. 2010;21:11-19. [PMID: 20018552 DOI: 10.1016/j.cytogfr.2009.11.005] [Cited by in Crossref: 674] [Cited by in F6Publishing: 659] [Article Influence: 51.8] [Reference Citation Analysis]
224 Vilarinho S, Erson-Omay EZ, Mitchell-Richards K, Cha C, Nelson-Williams C, Harmancı AS, Yasuno K, Günel M, Taddei TH. Exome analysis of the evolutionary path of hepatocellular adenoma-carcinoma transition, vascular invasion and brain dissemination. J Hepatol 2017;67:186-91. [PMID: 28323122 DOI: 10.1016/j.jhep.2017.03.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
225 Kumar M, Zhao X, Wang XW. Molecular carcinogenesis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: one step closer to personalized medicine? Cell Biosci. 2011;1:5. [PMID: 21711594 DOI: 10.1186/2045-3701-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
226 Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9:798-809. [PMID: 19851315 DOI: 10.1038/nrc2734] [Cited by in Crossref: 2500] [Cited by in F6Publishing: 2417] [Article Influence: 192.3] [Reference Citation Analysis]
227 Maylee H, Harada K, Igarashi S, Tohda G, Yamamoto M, Ren XS, Osawa T, Hasegawa Y, Takahashi N, Nakanuma Y. Case of telangiectatic/inflammatory hepatocellular adenoma arising in a patient with primary sclerosing cholangitis. Hepatol Res. 2012;42:611-618. [PMID: 22568458 DOI: 10.1111/j.1872-034X.2011.00962.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
228 Schumacher N, Rose-John S. ADAM17 Activity and IL-6 Trans-Signaling in Inflammation and Cancer. Cancers (Basel). 2019;11. [PMID: 31694340 DOI: 10.3390/cancers11111736] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 11.0] [Reference Citation Analysis]
229 Sung B, Prasad S, Yadav VR, Lavasanifar A, Aggarwal BB. Cancer and diet: How are they related? Free Radic Res 2011;45:864-79. [PMID: 21651450 DOI: 10.3109/10715762.2011.582869] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 3.5] [Reference Citation Analysis]
230 Huang E, Xue S, Zhang Z, Zhou J, Guan Y, Tang Y. Vinpocetine inhibits breast cancer cells growth in vitro and in vivo. Apoptosis 2012;17:1120-30. [DOI: 10.1007/s10495-012-0743-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
231 Nault JC, Bioulac-Sage P, Zucman-Rossi J. Hepatocellular benign tumors-from molecular classification to personalized clinical care. Gastroenterology. 2013;144:888-902. [PMID: 23485860 DOI: 10.1053/j.gastro.2013.02.032] [Cited by in Crossref: 199] [Cited by in F6Publishing: 145] [Article Influence: 22.1] [Reference Citation Analysis]
232 Jeannot E, Mellottee L, Bioulac-Sage P, Balabaud C, Scoazec JY, Tran Van Nhieu J, Bacq Y, Michalak S, Buob D, Laurent-Puig P, Rusyn I, Zucman-Rossi J; Groupe d'étude Génétique des Tumeurs Hépatiques (INSERM Network). Spectrum of HNF1A somatic mutations in hepatocellular adenoma differs from that in patients with MODY3 and suggests genotoxic damage. Diabetes 2010;59:1836-44. [PMID: 20393147 DOI: 10.2337/db09-1819] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 3.4] [Reference Citation Analysis]
233 Bioulac-sage P, Cubel G, Taouji S, Scoazec J, Leteurtre E, Paradis V, Sturm N, Van Nhieu JT, Wendum D, Bancel B, Ramos J, Paraf F, Saint Paul MC, Michalak S, Fabre M, Guettier C, Le Bail B, Zucman-rossi J, Balabaud C. Immunohistochemical Markers on Needle Biopsies Are Helpful for the Diagnosis of Focal Nodular Hyperplasia and Hepatocellular Adenoma Subtypes. American Journal of Surgical Pathology 2012;36:1691-9. [DOI: 10.1097/pas.0b013e3182653ece] [Cited by in Crossref: 89] [Cited by in F6Publishing: 25] [Article Influence: 8.9] [Reference Citation Analysis]
234 Nault JC, Zucman Rossi J. Molecular classification of hepatocellular adenomas. Int J Hepatol. 2013;2013:315947. [PMID: 23401783 DOI: 10.1155/2013/315947] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
235 Alison MR, Nicholson LJ, Lin WR. Chronic inflammation and hepatocellular carcinoma. Recent Results Cancer Res 2011;185:135-48. [PMID: 21822824 DOI: 10.1007/978-3-642-03503-6_8] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 3.8] [Reference Citation Analysis]
236 Raft MB, Jørgensen EN, Vainer B. Gene mutations in hepatocellular adenomas. Histopathology 2015;66:910-21. [PMID: 25195525 DOI: 10.1111/his.12539] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
237 Tang L, Wang K. Chronic Inflammation in Skin Malignancies. J Mol Signal 2016;11:2. [PMID: 31051015 DOI: 10.5334/1750-2187-11-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 3.7] [Reference Citation Analysis]
238 Riordan JD, Nadeau JH. Modeling progressive non-alcoholic fatty liver disease in the laboratory mouse. Mamm Genome 2014;25:473-86. [PMID: 24802098 DOI: 10.1007/s00335-014-9521-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
239 Bioulac-sage P, Laumonier H, Balabaud CP. Benign Hepatocellular Tumors. Practical Hepatic Pathology: A Diagnostic Approach. Elsevier; 2011. pp. 473-88. [DOI: 10.1016/b978-0-443-06803-4.00034-4] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
240 Putoczki TL, Thiem S, Loving A, Busuttil RA, Wilson NJ, Ziegler PK, Nguyen PM, Preaudet A, Farid R, Edwards KM. Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically. Cancer Cell. 2013;24:257-271. [PMID: 23948300 DOI: 10.1016/j.ccr.2013.06.017] [Cited by in Crossref: 242] [Cited by in F6Publishing: 226] [Article Influence: 26.9] [Reference Citation Analysis]
241 Truant S, Boleslawski E, Duhamel A, Bouras AF, Louvet A, Febvay C, Leteurtre E, Huet G, Zerbib P, Dharancy S. Tumor size of hepatocellular carcinoma in noncirrhotic liver: a controversial predictive factor for outcome after resection. Eur J Surg Oncol. 2012;38:1189-1196. [PMID: 22863304 DOI: 10.1016/j.ejso.2012.07.112] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 3.7] [Reference Citation Analysis]
242 Thapar M, Grapp O, Fisher C. Management of hepatic adenomatosis. Curr Gastroenterol Rep 2015;17:12. [PMID: 25740249 DOI: 10.1007/s11894-015-0434-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
243 Fukusato T, Soejima Y, Kondo F, Inoue M, Watanabe M, Takahashi Y, Aso T, Uozaki H, Sano K, Sanada Y, Niki T. Preserved or enhanced OATP1B3 expression in hepatocellular adenoma subtypes with nuclear accumulation of β-catenin. Hepatol Res 2015;45:E32-42. [PMID: 25418671 DOI: 10.1111/hepr.12453] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
244 Bayard Q, Caruso S, Couchy G, Rebouissou S, Bioulac Sage P, Balabaud C, Paradis V, Sturm N, de Muret A, Guettier C, Bonsang B, Copie C, Letouzé E, Calderaro J, Imbeaud S, Nault JC, Zucman-Rossi J. Recurrent chromosomal rearrangements of ROS1, FRK and IL6 activating JAK/STAT pathway in inflammatory hepatocellular adenomas. Gut 2020;69:1667-76. [PMID: 31907296 DOI: 10.1136/gutjnl-2019-319790] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
245 Pilati C, Amessou M, Bihl MP, Balabaud C, Nhieu JT, Paradis V, Nault JC, Izard T, Bioulac-Sage P, Couchy G, Poussin K, Zucman-Rossi J. Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. J Exp Med. 2011;208:1359-1366. [PMID: 21690253 DOI: 10.1084/jem.20110283] [Cited by in Crossref: 176] [Cited by in F6Publishing: 166] [Article Influence: 16.0] [Reference Citation Analysis]
246 Behari J. The Wnt/β-catenin signaling pathway in liver biology and disease. Expert Rev Gastroenterol Hepatol. 2010;4:745-756. [PMID: 21108594 DOI: 10.1586/egh.10.74] [Cited by in Crossref: 57] [Cited by in F6Publishing: 53] [Article Influence: 5.2] [Reference Citation Analysis]
247 Cassiman D, Libbrecht L, Verslype C, Meersseman W, Troisi R, Zucman-rossi J, Van Vlierberghe H. An adult male patient with multiple adenomas and a hepatocellular carcinoma: Mild Glycogen Storage Disease type Ia. Journal of Hepatology 2010;53:213-7. [DOI: 10.1016/j.jhep.2010.03.002] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
248 Li J, Liu J, Mao X, Tang Q, Lu H. IL-7 Receptor Blockade Inhibits IL-17-Producing γδ Cells and Suppresses Melanoma Development. Inflammation 2014;37:1444-52. [DOI: 10.1007/s10753-014-9869-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
249 Song D, Yu W, Ren Y, Zhu J, Wan C, Cai G, Guo J, Zhang W, Kong L. Discovery of bazedoxifene analogues targeting glycoprotein 130. European Journal of Medicinal Chemistry 2020;199:112375. [DOI: 10.1016/j.ejmech.2020.112375] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
250 Choi W, Kakar S. Atypical Hepatocellular Neoplasms: Review of Clinical, Morphologic, Immunohistochemical, Molecular, and Cytogenetic Features. Advances in Anatomic Pathology 2018;25:254-62. [DOI: 10.1097/pap.0000000000000189] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
251 He G, Karin M. NF-κB and STAT3 - key players in liver inflammation and cancer. Cell Res 2011;21:159-68. [PMID: 21187858 DOI: 10.1038/cr.2010.183] [Cited by in Crossref: 648] [Cited by in F6Publishing: 642] [Article Influence: 54.0] [Reference Citation Analysis]
252 Martínez-Pérez C, Kay C, Meehan J, Gray M, Dixon JM, Turnbull AK. The IL6-like Cytokine Family: Role and Biomarker Potential in Breast Cancer. J Pers Med 2021;11:1073. [PMID: 34834425 DOI: 10.3390/jpm11111073] [Reference Citation Analysis]
253 Chang CY, Hernandez-Prera JC, Roayaie S, Schwartz M, Thung SN. Changing epidemiology of hepatocellular adenoma in the United States: review of the literature. Int J Hepatol. 2013;2013:604860. [PMID: 23509632 DOI: 10.1155/2013/604860] [Cited by in Crossref: 56] [Cited by in F6Publishing: 42] [Article Influence: 6.2] [Reference Citation Analysis]
254 Schmidt-Arras D, Rose-John S. Endosomes as Signaling Platforms for IL-6 Family Cytokine Receptors. Front Cell Dev Biol 2021;9:688314. [PMID: 34141712 DOI: 10.3389/fcell.2021.688314] [Reference Citation Analysis]
255 Vollmer S, Haan C, Behrmann I. Oncostatin M up-regulates the ER chaperone Grp78/BiP in liver cells. Biochem Pharmacol. 2010;80:2066-2073. [PMID: 20650266 DOI: 10.1016/j.bcp.2010.07.015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
256 Ros PR, Goodman ZD. Genetics and imaging of hepatocellular adenomas: 2011 update. Invited commentary. Radiographics 2011;31:1543-5; discussion 1545. [PMID: 22103002 DOI: 10.1148/Radiographics.31.6.111543] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
257 Zucman-rossi J, Amessou M, Bioulac-sage P, Rebouissou S. Identification de mutations activatrices de gp130 dans la tumorigenèse hépatique. Med Sci (Paris) 2008;24:1113-4. [DOI: 10.1051/medsci/200824121113] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
258 Malchow S, Thaiss W, Jänner N, Waetzig GH, Gewiese-rabsch J, Garbers C, Yamamoto K, Rose-john S, Scheller J. Essential role of neutrophil mobilization in concanavalin A-induced hepatitis is based on classic IL-6 signaling but not on IL-6 trans-signaling. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2011;1812:290-301. [DOI: 10.1016/j.bbadis.2010.11.009] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
259 Moraga I, Wernig G, Wilmes S, Gryshkova V, Richter CP, Hong WJ, Sinha R, Guo F, Fabionar H, Wehrman TS, Krutzik P, Demharter S, Plo I, Weissman IL, Minary P, Majeti R, Constantinescu SN, Piehler J, Garcia KC. Tuning cytokine receptor signaling by re-orienting dimer geometry with surrogate ligands. Cell 2015;160:1196-208. [PMID: 25728669 DOI: 10.1016/j.cell.2015.02.011] [Cited by in Crossref: 93] [Cited by in F6Publishing: 86] [Article Influence: 13.3] [Reference Citation Analysis]
260 Johnson C, Han Y, Hughart N, McCarra J, Alpini G, Meng F. Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer. Transl Gastrointest Cancer 2012;1:58-70. [PMID: 22724089 DOI: 10.3978/j.issn.2224-4778.2011.11.02] [Cited by in F6Publishing: 61] [Reference Citation Analysis]
261 Ma Y, Karunakaran T, Veeraraghavan VP, Mohan SK, Li S. Sesame Inhibits Cell Proliferation and Induces Apoptosis through Inhibition of STAT-3 Translocation in Thyroid Cancer Cell Lines (FTC-133). Biotechnol Bioproc E 2019;24:646-52. [DOI: 10.1007/s12257-019-0151-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
262 Weinhouse C, Bergin IL, Harris C, Dolinoy DC. Stat3 is a candidate epigenetic biomarker of perinatal Bisphenol A exposure associated with murine hepatic tumors with implications for human health. Epigenetics 2015;10:1099-110. [PMID: 26542749 DOI: 10.1080/15592294.2015.1107694] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
263 Marotta LL, Almendro V, Marusyk A, Shipitsin M, Schemme J, Walker SR, Bloushtain-Qimron N, Kim JJ, Choudhury SA, Maruyama R. The JAK2/STAT3 signaling pathway is required for growth of CD44 CD24 stem cell-like breast cancer cells in human tumors. J Clin Invest. 2011;121:2723-2735. [PMID: 21633165 DOI: 10.1172/jci44745] [Cited by in Crossref: 584] [Cited by in F6Publishing: 388] [Article Influence: 53.1] [Reference Citation Analysis]
264 Ladeiro Y, Zucman-rossi J. Micro-ARN (miARN) et cancer : le cas des tumeurs hépatocellulaires. Med Sci (Paris) 2009;25:467-72. [DOI: 10.1051/medsci/2009255467] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
265 Griffiths DS, Li J, Dawson MA, Trotter MW, Cheng YH, Smith AM, Mansfield W, Liu P, Kouzarides T, Nichols J, Bannister AJ, Green AR, Göttgens B. LIF-independent JAK signalling to chromatin in embryonic stem cells uncovered from an adult stem cell disease. Nat Cell Biol 2011;13:13-21. [PMID: 21151131 DOI: 10.1038/ncb2135] [Cited by in Crossref: 91] [Cited by in F6Publishing: 75] [Article Influence: 7.6] [Reference Citation Analysis]
266 Ryu J, Kang M, Lee MS, Kim HJ, Nam SH, Song HE, Lee D, Lee JW. Cross talk between the TM4SF5/focal adhesion kinase and the interleukin-6/STAT3 pathways promotes immune escape of human liver cancer cells. Mol Cell Biol 2014;34:2946-60. [PMID: 24912675 DOI: 10.1128/MCB.00660-14] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
267 Li Z, Zheng W, Wang Z, Zeng Z, Zhan H, Li C, Zhou L, Yan C, Spitsbergen JM, Gong Z. A transgenic zebrafish liver tumor model with inducible Myc expression reveals conserved Myc signatures with mammalian liver tumors. Dis Model Mech. 2013;6:414-423. [PMID: 23038063 DOI: 10.1242/dmm.010462] [Cited by in Crossref: 59] [Cited by in F6Publishing: 53] [Article Influence: 5.9] [Reference Citation Analysis]
268 Dougan M, Li D, Neuberg D, Mihm M, Googe P, Wong KK, Dranoff G. A dual role for the immune response in a mouse model of inflammation-associated lung cancer. J Clin Invest 2011;121:2436-46. [PMID: 21537082 DOI: 10.1172/JCI44796] [Cited by in Crossref: 64] [Cited by in F6Publishing: 42] [Article Influence: 5.8] [Reference Citation Analysis]
269 Chang Q, Daly L, Bromberg J. The IL-6 feed-forward loop: a driver of tumorigenesis. Semin Immunol 2014;26:48-53. [PMID: 24613573 DOI: 10.1016/j.smim.2014.01.007] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 6.6] [Reference Citation Analysis]
270 Longerich T, Schirmacher P. A new link between cancer and inflammation? Journal of Hepatology 2009;51:230-2. [DOI: 10.1016/j.jhep.2009.03.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
271 Schmidt S, Schumacher N, Schwarz J, Tangermann S, Kenner L, Schlederer M, Sibilia M, Linder M, Altendorf-Hofmann A, Knösel T, Gruber ES, Oberhuber G, Bolik J, Rehman A, Sinha A, Lokau J, Arnold P, Cabron AS, Zunke F, Becker-Pauly C, Preaudet A, Nguyen P, Huynh J, Afshar-Sterle S, Chand AL, Westermann J, Dempsey PJ, Garbers C, Schmidt-Arras D, Rosenstiel P, Putoczki T, Ernst M, Rose-John S. ADAM17 is required for EGF-R-induced intestinal tumors via IL-6 trans-signaling. J Exp Med 2018;215:1205-25. [PMID: 29472497 DOI: 10.1084/jem.20171696] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 9.8] [Reference Citation Analysis]
272 Amaddeo G, Guichard C, Imbeaud S, Zucman-Rossi J. Next-generation sequencing identified new oncogenes and tumor suppressor genes in human hepatic tumors. Oncoimmunology 2012;1:1612-3. [PMID: 23264911 DOI: 10.4161/onci.21480] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 19.0] [Reference Citation Analysis]
273 Li L, Zheng YL, Jiang C, Fang S, Zeng TT, Zhu YH, Li Y, Xie D, Guan XY. HN1L-mediated transcriptional axis AP-2γ/METTL13/TCF3-ZEB1 drives tumor growth and metastasis in hepatocellular carcinoma. Cell Death Differ 2019;26:2268-83. [PMID: 30778199 DOI: 10.1038/s41418-019-0301-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
274 Eddie SL, Childs AJ, Jabbour HN, Anderson RA. Developmentally regulated IL6-type cytokines signal to germ cells in the human fetal ovary. Mol Hum Reprod 2012;18:88-95. [PMID: 21965347 DOI: 10.1093/molehr/gar061] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
275 Johnson DE, O'Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15:234-248. [PMID: 29405201 DOI: 10.1038/nrclinonc.2018.8] [Cited by in Crossref: 667] [Cited by in F6Publishing: 689] [Article Influence: 166.8] [Reference Citation Analysis]
276 Aparicio-Siegmund S, Sommer J, Monhasery N, Schwanbeck R, Keil E, Finkenstädt D, Pfeffer K, Rose-John S, Scheller J, Garbers C. Inhibition of protein kinase II (CK2) prevents induced signal transducer and activator of transcription (STAT) 1/3 and constitutive STAT3 activation. Oncotarget 2014;5:2131-48. [PMID: 24742922 DOI: 10.18632/oncotarget.1852] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 3.7] [Reference Citation Analysis]
277 Heim D, Gil-Ibanez I, Herden J, Parplys AC, Borgmann K, Schmidt-Arras D, Lohse AW, Rose-John S, Wege H. Constitutive gp130 activation rapidly accelerates the transformation of human hepatocytes via an impaired oxidative stress response. Oncotarget 2016;7:55639-48. [PMID: 27489351 DOI: 10.18632/oncotarget.10956] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
278 Nevzorova YA, Liedtke C. Sh(i)pping signals protect against Stat3-driven liver cancer. Hepatology. 2012;55:322-324. [PMID: 22190379 DOI: 10.1002/hep.24742] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
279 Calderaro J, Nault JC, Balabaud C, Couchy G, Saint-paul M, Azoulay D, Mehdaoui D, Luciani A, Zafrani ES, Bioulac-sage P, Zucman-rossi J. Inflammatory hepatocellular adenomas developed in the setting of chronic liver disease and cirrhosis. Mod Pathol 2016;29:43-50. [DOI: 10.1038/modpathol.2015.119] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
280 Castain C, Sempoux C, Brunt EM, Causse O, Heitzmann A, Hernandez-prera JC, Le Bail B, Schirmacher P, Thung SN, Balabaud C, Bioulac-sage P. Coexistence of inflammatory hepatocellular adenomas with HNF1α-inactivated adenomas: is there an association? Histopathology 2014;64:890-5. [DOI: 10.1111/his.12326] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
281 Ji X, Xue Y, Wu Y, Feng F, Gao X. High-expressed CKS2 is associated with hepatocellular carcinoma cell proliferation through down-regulating PTEN. Pathology - Research and Practice 2018;214:436-41. [DOI: 10.1016/j.prp.2017.12.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
282 Bioulac-Sage P, Sempoux C, Balabaud C. Hepatocellular Adenomas: Morphology and Genomics. Gastroenterol Clin North Am 2017;46:253-72. [PMID: 28506364 DOI: 10.1016/j.gtc.2017.01.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
283 Nault JC, Couchy G, Balabaud C, Morcrette G, Caruso S, Blanc JF, Bacq Y, Calderaro J, Paradis V, Ramos J, Scoazec JY, Gnemmi V, Sturm N, Guettier C, Fabre M, Savier E, Chiche L, Labrune P, Selves J, Wendum D, Pilati C, Laurent A, De Muret A, Le Bail B, Rebouissou S, Imbeaud S, Bioulac-Sage P, Letouzé E, Zucman-Rossi J; GENTHEP Investigators. Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation. Gastroenterology 2017;152:880-894.e6. [PMID: 27939373 DOI: 10.1053/j.gastro.2016.11.042] [Cited by in Crossref: 168] [Cited by in F6Publishing: 144] [Article Influence: 28.0] [Reference Citation Analysis]
284 Yazdani Z, Rafiei A, Golpour M, Zafari P, Moonesi M, Ghaffari S. IL‐35, a double‐edged sword in cancer. J Cell Biochem 2020;121:2064-76. [DOI: 10.1002/jcb.29441] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
285 Nault JC, Datta S, Imbeaud S, Franconi A, Mallet M, Couchy G, Letouzé E, Pilati C, Verret B, Blanc JF, Balabaud C, Calderaro J, Laurent A, Letexier M, Bioulac-Sage P, Calvo F, Zucman-Rossi J. Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nat Genet 2015;47:1187-93. [PMID: 26301494 DOI: 10.1038/ng.3389] [Cited by in Crossref: 266] [Cited by in F6Publishing: 252] [Article Influence: 38.0] [Reference Citation Analysis]
286 Mankan AK, Greten FR. Inhibiting signal transducer and activator of transcription 3: rationality and rationale design of inhibitors. Expert Opin Investig Drugs 2011;20:1263-75. [PMID: 21751940 DOI: 10.1517/13543784.2011.601739] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 5.4] [Reference Citation Analysis]
287 Luan M, Song F, Qu S, Meng X, Ji J, Duan Y, Sun C, Si H, Zhai H. Multi-omics integrative analysis and survival risk model construction of non-small cell lung cancer based on The Cancer Genome Atlas datasets. Oncol Lett 2020;20:58. [PMID: 32863893 DOI: 10.3892/ol.2020.11919] [Reference Citation Analysis]
288 Garcovich M, Faccia M, Meloni F, Bertolini E, de Sio I, Calabria G, Francica G, Vidili G, Riccardi L, Zocco MA, Ainora ME, Ponziani FR, De Gaetano AM, Gasbarrini A, Rapaccini GL, Pompili M. Contrast-enhanced ultrasound patterns of hepatocellular adenoma: an Italian multicenter experience. J Ultrasound 2019;22:157-65. [PMID: 30306412 DOI: 10.1007/s40477-018-0322-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
289 Deniz K, Umetsu SE, Ferrell L, Yılmaz F, Güllüoğlu M, Sağol Ö, Doğusoy GB, Kırımlıoğlu H, Turhan N, Doran F, Kepil N, Çelikel ÇA, Nart D, Özgüven BY, Ceyran B, Karadağ N, Kır G, Erden E, Yılmaz G, Akyol G. Hepatocellular adenomas in the Turkish population: reclassification according to updated World Health Organization criteria. Histopathology 2021;79:23-33. [PMID: 33406290 DOI: 10.1111/his.14330] [Reference Citation Analysis]
290 Valin A, Pablos JL. The Role of the Transcriptional Regulation of Stromal Cells in Chronic Inflammation. Biomolecules 2015;5:2723-57. [PMID: 26501341 DOI: 10.3390/biom5042723] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
291 Kamimura D, Arima Y, Hirano T, Ogura H, Murakami M. IL-6 and Inflammatory Diseases. In: Yoshimoto T, Yoshimoto T, editors. Cytokine Frontiers. Tokyo: Springer Japan; 2014. pp. 53-78. [DOI: 10.1007/978-4-431-54442-5_2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
292 Deva AK, Turner SD, Kadin ME, Magnusson MR, Prince HM, Miranda RN, Inghirami GG, Adams WP Jr. Etiology of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): Current Directions in Research. Cancers (Basel) 2020;12:E3861. [PMID: 33371292 DOI: 10.3390/cancers12123861] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
293 Tsai WT, Lo YC, Wu MS, Li CY, Kuo YP, Lai YH, Tsai Y, Chen KC, Chuang TH, Yao CH, Lee JC, Hsu LC, Hsu JT, Yu GY. Mycotoxin Patulin Suppresses Innate Immune Responses by Mitochondrial Dysfunction and p62/Sequestosome-1-dependent Mitophagy. J Biol Chem 2016;291:19299-311. [PMID: 27458013 DOI: 10.1074/jbc.M115.686683] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
294 Liu L, Liu YL, Liu GX, Chen X, Yang K, Yang YX, Xie Q, Gan HK, Huang XL, Gan HT. Curcumin ameliorates dextran sulfate sodium-induced experimental colitis by blocking STAT3 signaling pathway. Int Immunopharmacol. 2013;17:314-320. [PMID: 23856612 DOI: 10.1016/j.intimp.2013.06.020] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 5.0] [Reference Citation Analysis]
295 Thiem S, Pierce TP, Palmieri M, Putoczki TL, Buchert M, Preaudet A, Farid RO, Love C, Catimel B, Lei Z, Rozen S, Gopalakrishnan V, Schaper F, Hallek M, Boussioutas A, Tan P, Jarnicki A, Ernst M. mTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in mice. J Clin Invest 2013;123:767-81. [PMID: 23321674 DOI: 10.1172/JCI65086] [Cited by in Crossref: 25] [Cited by in F6Publishing: 39] [Article Influence: 2.8] [Reference Citation Analysis]
296 Shanbhogue A, Shah SN, Zaheer A, Prasad SR, Takahashi N, Vikram R. Hepatocellular adenomas: current update on genetics, taxonomy, and management. J Comput Assist Tomogr. 2011;35:159-166. [PMID: 21412084 DOI: 10.1097/RCT.0b013e31820bad61] [Cited by in Crossref: 27] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
297 Walther Z, Jain D. Molecular pathology of hepatic neoplasms: classification and clinical significance. Patholog Res Int. 2011;2011:403929. [PMID: 21559202 DOI: 10.4061/2011/403929] [Cited by in Crossref: 19] [Cited by in F6Publishing: 26] [Article Influence: 1.7] [Reference Citation Analysis]
298 Goodman ZD, Terracciano LM, Wee A. Tumours and tumour-like lesions of the liver. MacSween's Pathology of the Liver. Elsevier; 2012. pp. 761-851. [DOI: 10.1016/b978-0-7020-3398-8.00014-3] [Cited by in Crossref: 21] [Article Influence: 2.1] [Reference Citation Analysis]
299 Choi WT, Kakar S. Immunohistochemistry in the Diagnosis of Hepatocellular Carcinoma. Gastroenterol Clin North Am. 2017;46:311-325. [PMID: 28506367 DOI: 10.1016/j.gtc.2017.01.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
300 Song W, Wang J, Liu H, Zhu C, Xu F, Qian L, Shen Z, Zhu J, Yin S, Qin J, Chen L, Wu D, Nashan B, Shan G, Xiao W, Zhou Y. Effects of LncRNA Lnc-LIF-AS on cell proliferation, migration and invasion in a human cervical cancer cell line. Cytokine 2019;120:165-75. [PMID: 31085454 DOI: 10.1016/j.cyto.2019.05.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
301 Sansone P, Bromberg J. Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol. 2012;30:1005-1014. [PMID: 22355058 DOI: 10.1200/jco.2010.31.8907] [Cited by in Crossref: 341] [Cited by in F6Publishing: 199] [Article Influence: 34.1] [Reference Citation Analysis]
302 Jarnicki A, Putoczki T, Ernst M. Stat3: linking inflammation to epithelial cancer - more than a “gut” feeling? Cell Div. 2010;5:14. [PMID: 20478049 DOI: 10.1186/1747-1028-5-14] [Cited by in Crossref: 174] [Cited by in F6Publishing: 165] [Article Influence: 14.5] [Reference Citation Analysis]
303 Li S, Priceman SJ, Xin H, Zhang W, Deng J, Liu Y, Huang J, Zhu W, Chen M, Hu W. Icaritin inhibits JAK/STAT3 signaling and growth of renal cell carcinoma. PLoS One. 2013;8:e81657. [PMID: 24324713 DOI: 10.1371/journal.pone.0081657] [Cited by in Crossref: 50] [Cited by in F6Publishing: 57] [Article Influence: 5.6] [Reference Citation Analysis]
304 Sakellariou S, Morgan Y, Heaton N, Portmann B, Quaglia A, Tobal K. New monoallelic (partial tandem duplication) mutation of HNF1a gene in steatotic hepatocellular adenoma. Eur J Gastroenterol Hepatol 2011;23:623-7. [PMID: 21566527 DOI: 10.1097/MEG.0b013e328347964d] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
305 Zucman-Rossi J. Molecular classification of hepatocellular carcinoma. Dig Liver Dis 2010;42 Suppl 3:S235-41. [PMID: 20547309 DOI: 10.1016/S1590-8658(10)60511-7] [Cited by in Crossref: 54] [Cited by in F6Publishing: 28] [Article Influence: 4.5] [Reference Citation Analysis]
306 Arshad S, Naveed M, Ullia M, Javed K, Butt A, Khawar M, Amjad F. Targeting STAT-3 signaling pathway in cancer for development of novel drugs: Advancements and challenges. Genet Mol Biol 2020;43:e20180160. [PMID: 32167126 DOI: 10.1590/1678-4685-GMB-2018-0160] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
307 Pilati C, Zucman-rossi J. Mutations leading to constitutive active gp130/JAK1/STAT3 pathway. Cytokine & Growth Factor Reviews 2015;26:499-506. [DOI: 10.1016/j.cytogfr.2015.07.010] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
308 Chen J, Pitmon E, Wang K. Microbiome, inflammation and colorectal cancer. Semin Immunol. 2017;32:43-53. [PMID: 28982615 DOI: 10.1016/j.smim.2017.09.006] [Cited by in Crossref: 102] [Cited by in F6Publishing: 101] [Article Influence: 20.4] [Reference Citation Analysis]
309 Dokmak S, Paradis V, Vilgrain V, Sauvanet A, Farges O, Valla D, Bedossa P, Belghiti J. A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas. Gastroenterology. 2009;137:1698-1705. [PMID: 19664629 DOI: 10.1053/j.gastro.2009.07.061] [Cited by in Crossref: 266] [Cited by in F6Publishing: 199] [Article Influence: 20.5] [Reference Citation Analysis]
310 Lokau J, Schoeder V, Haybaeck J, Garbers C. Jak-Stat Signaling Induced by Interleukin-6 Family Cytokines in Hepatocellular Carcinoma. Cancers (Basel) 2019;11:E1704. [PMID: 31683891 DOI: 10.3390/cancers11111704] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
311 Longerich T, Breuhahn K, Schirmacher P. Molecular Pathology of Liver Tumors. In: Cheng L, Eble JN, editors. Molecular Surgical Pathology. New York: Springer; 2013. pp. 43-63. [DOI: 10.1007/978-1-4614-4900-3_3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
312 Agostini-vulaj D, Sharma AK, Findeis-hosey JJ, Mcmahon LA, Gonzalez RS. Distinction between inflammatory hepatocellular adenoma and mass effect on liver sampling. Human Pathology 2017;61:105-10. [DOI: 10.1016/j.humpath.2016.12.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
313 Roca H, McCauley LK. Inflammation and skeletal metastasis. Bonekey Rep 2015;4:706. [PMID: 26131358 DOI: 10.1038/bonekey.2015.75] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
314 Xiao H, Bid HK, Chen X, Wu X, Wei J, Bian Y, Zhao C, Li H, Li C, Lin J. Repositioning Bazedoxifene as a novel IL-6/GP130 signaling antagonist for human rhabdomyosarcoma therapy. PLoS One 2017;12:e0180297. [PMID: 28672024 DOI: 10.1371/journal.pone.0180297] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
315 Kang S, Narazaki M, Metwally H, Kishimoto T. Historical overview of the interleukin-6 family cytokine. J Exp Med 2020;217:e20190347. [PMID: 32267936 DOI: 10.1084/jem.20190347] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 9.5] [Reference Citation Analysis]
316 Schaper F, Rose-john S. Interleukin-6: Biology, signaling and strategies of blockade. Cytokine & Growth Factor Reviews 2015;26:475-87. [DOI: 10.1016/j.cytogfr.2015.07.004] [Cited by in Crossref: 273] [Cited by in F6Publishing: 254] [Article Influence: 39.0] [Reference Citation Analysis]
317 Inagaki-Ohara K, Kondo T, Ito M, Yoshimura A. SOCS, inflammation, and cancer. JAKSTAT. 2013;2:e24053. [PMID: 24069550 DOI: 10.4161/jkst.24053] [Cited by in Crossref: 67] [Cited by in F6Publishing: 102] [Article Influence: 7.4] [Reference Citation Analysis]
318 Nault JC, Zucman-Rossi J. TERT promoter mutations in primary liver tumors. Clin Res Hepatol Gastroenterol. 2016;40:9-14. [PMID: 26336998 DOI: 10.1016/j.clinre.2015.07.006] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 7.9] [Reference Citation Analysis]
319 van Aalten SM, Witjes CD, de Man RA, Ijzermans JN, Terkivatan T. Can a decision-making model be justified in the management of hepatocellular adenoma? Liver Int. 2012;32:28-37. [PMID: 22098685 DOI: 10.1111/j.1478-3231.2011.02667.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
320 Wang BX, Platanias LC, Fish EN. STAT Activation in Malignancies: Roles in Tumor Progression and in the Generation of Antineoplastic Effects of IFNs. Journal of Interferon & Cytokine Research 2013;33:181-8. [DOI: 10.1089/jir.2012.0154] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
321 Heymans S, Corsten MF, Verhesen W, Carai P, van Leeuwen RE, Custers K, Peters T, Hazebroek M, Stöger L, Wijnands E. Macrophage microRNA-155 promotes cardiac hypertrophy and failure. Circulation. 2013;128:1420-1432. [PMID: 23956210 DOI: 10.1161/circulationaha.112.001357] [Cited by in Crossref: 159] [Cited by in F6Publishing: 88] [Article Influence: 17.7] [Reference Citation Analysis]
322 Nault JC, Paradis V, Cherqui D, Vilgrain V, Zucman-Rossi J. Molecular classification of hepatocellular adenoma in clinical practice. J Hepatol. 2017;67:1074-1083. [PMID: 28733222 DOI: 10.1016/j.jhep.2017.07.009] [Cited by in Crossref: 71] [Cited by in F6Publishing: 60] [Article Influence: 14.2] [Reference Citation Analysis]
323 Zhang J, Lu Y, Yue X, Li H, Luo X, Wang Y, Wang K, Wan J. MiR-124 suppresses growth of human colorectal cancer by inhibiting STAT3. PLoS One 2013;8:e70300. [PMID: 23940556 DOI: 10.1371/journal.pone.0070300] [Cited by in Crossref: 73] [Cited by in F6Publishing: 80] [Article Influence: 8.1] [Reference Citation Analysis]
324 Ernst M, Ramsay RG. Colorectal cancer mouse models: integrating inflammation and the stroma. J Gastroenterol Hepatol 2012;27:39-50. [PMID: 22188027 DOI: 10.1111/j.1440-1746.2011.06883.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
325 Sander LE, Sackett SD, Dierssen U, Beraza N, Linke RP, Müller M, Blander JM, Tacke F, Trautwein C. Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function. J Exp Med. 2010;207:1453-1464. [PMID: 20530204 DOI: 10.1084/jem.20091474] [Cited by in Crossref: 224] [Cited by in F6Publishing: 222] [Article Influence: 18.7] [Reference Citation Analysis]
326 Shkhyan R, Van Handel B, Bogdanov J, Lee S, Yu Y, Scheinberg M, Banks NW, Limfat S, Chernostrik A, Franciozi CE, Alam MP, John V, Wu L, Ferguson GB, Nsair A, Petrigliano FA, Vangsness CT, Vadivel K, Bajaj P, Wang L, Liu NQ, Evseenko D. Drug-induced modulation of gp130 signalling prevents articular cartilage degeneration and promotes repair. Ann Rheum Dis 2018;77:760-9. [PMID: 29436471 DOI: 10.1136/annrheumdis-2017-212037] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
327 Pérez Rojas J, Guarín Corredor MJ, Artes Martinez MJ, Vera Sempere FJ, Brisa Estelles C, Huart Peris MC, Hernandez Giron S. [Immunophenotypic classification of 3 cases of hepatocellular adenoma. Differential diagnosis with focal nodular hyperplasia]. Gastroenterol Hepatol 2013;36:388-95. [PMID: 23664829 DOI: 10.1016/j.gastrohep.2013.02.013] [Reference Citation Analysis]
328 Bioulac-sage P, Cubel G, Balabaud C. Pathological diagnosis of hepatocellular adenoma in clinical practice. Diagnostic Histopathology 2011;17:521-9. [DOI: 10.1016/j.mpdhp.2011.10.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
329 Flynn CM, Kespohl B, Daunke T, Garbers Y, Düsterhöft S, Rose-John S, Haybaeck J, Lokau J, Aparicio-Siegmund S, Garbers C. Interleukin-6 controls recycling and degradation, but not internalization of its receptors. J Biol Chem 2021;296:100434. [PMID: 33610555 DOI: 10.1016/j.jbc.2021.100434] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]